University of South Florida

Digital Commons @ University of South Florida
Graduate Theses and Dissertations

Graduate School

November 2021

The Role Of Cpeb2 Alternative Splicing In TNBC Metastasis
Shaun C. Stevens
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the Cell Biology Commons, and the Molecular Biology Commons

Scholar Commons Citation
Stevens, Shaun C., "The Role Of Cpeb2 Alternative Splicing In TNBC Metastasis" (2021). Graduate Theses
and Dissertations.
https://digitalcommons.usf.edu/etd/9237

This Dissertation is brought to you for free and open access by the Graduate School at Digital Commons @
University of South Florida. It has been accepted for inclusion in Graduate Theses and Dissertations by an
authorized administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

The Role Of Cpeb2 Alternative Splicing In TNBC Metastasis

by

Shaun C. Stevens

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
with a concentration in Cell and Molecular Biology
Department of Cell Biology, Microbiology and Molecular Biology
College of Arts and Sciences
University of South Florida

Co-Major Professor: Charles Chalfant, Ph.D.
Co-Major Professor: Margaret Park, Ph.D.
Sandy Westerheide, Ph.D.
Meera Nanjundan, Ph.D.
Jason Carlyon, Ph.D.

Date of Approval:
November 5, 2021

Keywords: IRES, Breast Cancer, hnRNPR, SRSF3
Copyright © 2021, Shaun C. Stevens

DEDICATION
This dissertation is dedicated to my wonderful wife Danielle, whose support and
encouragement have been with me through every aspect of this endeavor. Mere words
cannot express the gratitude which fills me when I contemplate the gravity of her
sacrifice through this process. I also dedicate this to my six incredible children, who
have been a source of profound motivation to press on and demonstrate resilience in
pursuing your goals.

ACKNOWLEDGMENTS
I would like to extend my warmest thanks and most sincere gratitude to my comentors, Dr. Margaret Park and Dr. Charles Chalfant. They have provided an
abundance of opportunities and guidance to explore my research interests. Without
their intellectual advice and continual help, none of these accomplishments would have
been possible. They have inspired a deep appreciation for the complex world of RNA
cancer biology. My sincerest thanks go to Dr. Margaret Park. Her belief in my ability to
succeed in this endeavor and her contagious enthusiasm has given me the courage to
stay the course. Also, I would like to thank Dr. Charles Chalfant for providing focused
guidance and an abundance of resources for my research goals. His support in the
direction of my research was paramount to my success.
I would also like to thank my committee members, Dr. Sandy Westerheide, Dr.
Meera Nanjundan, and Dr. Jason Carlyon, for their support and insightful feedback
during our discussions throughout the years. I thank Dr. Westerheide for her
encouragement many years ago to pursue this accomplishment. I would also like to
thank Dr. Beth Jones-Mason how many years ago introduced me to cancer research
and has been a source of great advice and encouragement through this process. My
gratitude also goes to the Graduate Program Director, Dr. Brant Burkhardt, for providing
guidance, clarity, and encouragement to ensure I achieved my goals.

I would like to thank my fellow lab members, Emily Mayo, Meagan Horton, Dr.
Christina Moss, Anika Ali, Kenny Maus, and Dr. Daniel Stephenson, for providing great
feedback and suggestions during our interactions through the years. I would also like to
thank Dr. Andrew Deonarine for giving me advice on navigating graduate school and his
willingness to discuss my research anytime. Thank you to Dr. James DeLigio, for his
work as co-author, and to authors Gina Nazario-Munoz, Dr. Patrick MacKnight, and Keli
Doe whose contributions made our publication possible.
I would like to thank my mother and father, Gary, and Claudia, who have always
supported my ideas and believe that I can achieve any goal I set out to accomplish. I
want to thank my kids for their inspiration, love, and their patience. Mostly, I want to
thank my wife Danielle for her unfailing support, encouragement, and love regardless of
any obstacles we faced. She truly is the greatest partner in life that I could have ever
wished for. Thank You.

TABLE OF CONTENTS
List of Tables ................................................................................................................... iii
List of Figures .................................................................................................................. iv
List of Abbreviations ........................................................................................................ vi
Abstract ........................................................................................................................... ix
Chapter One: Introduction ............................................................................................... 1
Alternative mRNA Splicing.................................................................................... 1
Alternative Splicing Mechanism and Regulation ................................................... 2
Serine/Arginine-Rich Splicing Factor Proteins ...................................................... 5
Cytoplasmic Polyadenylation Element Binding Protein2 (CPEB2) ....................... 7
Epithelial-Mesenchymal Transition ..................................................................... 10
Anoikis Resistance ............................................................................................. 12
Cap-Independent mRNA Translation.................................................................. 14
Triple-Negative Breast Cancer (TNBC) .............................................................. 17
Alternative mRNA Splicing of CPEB2 in TNBC .................................................. 18
Hypothesis and Specific Aims ............................................................................ 19
Chapter Two: Serine/arginine-rich Splicing Factor 3 Modulates the Alternative
Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 ....................... 21
Abstract .............................................................................................................. 21
Introduction ......................................................................................................... 22
Materials and Methods ....................................................................................... 25
Cell Culture and Reagents ....................................................................... 25
Western Blotting ...................................................................................... 25
Quantitative Reverse Transcriptase-Polymerase Chain Reaction ........... 26
siRNA Treatment and Plasmid Transfection ............................................ 26
Anoikis Resistance Assay ........................................................................ 26
Competitive Quantitative RT-PCR ........................................................... 27
RNA Binding Assays ................................................................................ 28
Electrophoretic Mobility Shift Assay ......................................................... 28
Minigene Construct and Plasmids ........................................................... 28
Biostatistics .............................................................................................. 29
Results ............................................................................................................... 30
Unbiased Proteomic Analysis Identified SRSF3 Association with
Exon Four of CPEB2 ......................................................................... 30
i

Downregulation of SRSF3 Resulted in Reduced Inclusion of Exon
Four into the Mature CPEB2 mRNA Transcript .................................. 34
The Consensus RNA cis-element for SRSF3 is Essential for the
Inclusion of Exon Four in CPEB2 ....................................................... 36
SRSF3 Regulates Anoikis Sensitivity in TNBC Cells by Enhancing
the Inclusion of Exon Four in CPEB2 mRNA ...................................... 41
Expression of SRSF3 is Enhanced in TNBC and Basal-like Breast
Cancer ................................................................................................ 43
Discussion .......................................................................................................... 45
Chapter Three: The Mechanism of Translational Regulation of HIF1 and TWIST1
mRNA via CPEB2A and CPEB2B Isoforms ............................................................. 50
Abstract .............................................................................................................. 50
Introduction ......................................................................................................... 51
Materials and Methods ....................................................................................... 56
Cell Culture and Reagents ....................................................................... 56
Western Blotting ...................................................................................... 56
Plasmid construction ................................................................................ 56
Plasmid Transfection ............................................................................... 57
UV Cross-linking and Co-immunoprecipitation ........................................ 57
Quantitative Reverse Transcriptase-Polymerase Chain Reaction ........... 58
RNA Binding Assays ................................................................................ 58
USB Poly(A) Tail-Length Assay ............................................................... 58
Co-immunoprecipitation and Proteomic Analysis ..................................... 59
CPEB2 Exon four Binding Assay ............................................................. 59
Immunofluorescence................................................................................ 60
Subcellular Fractionation Assay ............................................................... 60
Results ............................................................................................................... 60
CPEB2A Binds to CPE 1 and 2 Sites of TWIST1 and CPE 1 Site
of HIF1 3' UTR and Regulates Polyadenylation .................................... 60
CPEB2A and CPEB2B Associate with Polyadenylation Complex
Proteins.................................................................................................... 65
CPEB2A and CPEB2B localize to the nucleus and cytoplasm ................ 68
CPEB2A and CPEB2B protein association .............................................. 70
Discussion .......................................................................................................... 71
Chapter Four: Discussion and Conclusions .................................................................. 77
Literature Cited .............................................................................................................. 83
Appendix A: Copyright Permissions for Chapter Two ................................................. 108

ii

LIST OF TABLES
Table 1:

RNA trans-splicing factor candidate screen utilizing siRNA for
CPEB2A/B Protein Ratio.......................................................................... 31

iii

LIST OF FIGURES
Figure 1:

SRSF3/SRp20 specifically binds to exon four in CPEB2 pre-mRNA ....... 32

Figure 2:

Downregulation of SRSF3 decreases exon four inclusion in
endogenous CPEB2 transcripts and correlates to a loss of CPEB2B
protein expression ................................................................................... 35

Figure 3:

Varying levels of SRSF3 in TNBC cells affects the CPEB2
mRNA isoform ratio at exon four.............................................................. 38

Figure 4:

A Mutational analysis of SRSF3 RNA cis-element indicates
the pentameric cis-element is essential for the inclusion of
exon four in CPEB2 ................................................................................. 40

Figure 5:

SRSF3 modulates the TNBC cells' sensitivity to anoikis cell death
due to expression of CPEB2B ................................................................. 42

Figure 6:

SRSF3 is over-represented in the most aggressive and metastatic
breast cancers in The Cancer Genome Atlas .......................................... 44

Figure 7:

Proposed pathway for the mechanism of SRSF3 and CPEB2
splicing in the SRSF3/CPEB2B splicing paradigm constituting
progression towards metastatic TNBC..................................................... 49

Figure 8:

CPEB2A and CPEB2B HIF13'CPE binding differs but poly(A)
of HIF1 mRNA by both CPEB2 isoforms is consistent ........................... 62

Figure 9:

CPEB2A and CPEB2B TWIST1 3'CPE mRNA binding and
poly(A) differs........................................................................................... 64

Figure 10:

CPEB2B forms novel protein complexes ................................................. 66

Figure 11:

Nuclear and Cytoplasmic Localization of CPEB2A and CPEB2B ............ 68

Figure 12:

CPEB2A and CPEB2B protein isoforms localize to the cytoplasm
and nucleus independent of cellular stress .............................................. 69

Figure 13:

CPEB2A and CPEB2 protein interaction.................................................. 70

Figure 14:

CPEB2A protein isoform inhibits TWIST1 mRNA translation ................... 75
iv

Figure 15:

Mechanism of Translational regulation by CPEB2A/CPEB2B
interaction and IRES cap-independent translational activation ................ 76

v

LIST OF ABBREVIATIONS
3’UTR

3’ Untranslated Region

5’UTR

5’ Untranslated Region

AnR

Anoikis Resistance

AS

Alternative pre-mRNA Splicing

ASO

Antisense Oligonucleotide

BL1

Basal-like 1

BL2

Basal-like 2

BRCA

Breast Invasive Carcinoma Cohort

BS

Branch Site

CFL1

Cofilin1

CLIP-seq

Cross-Linking Immunoprecipitation – Next Generation Sequencing

Clk1/4

CDC-like Kinase 1 and 4

CPE

Cytoplasmic Polyadenylation Element

CPEB

Cytoplasmic Polyadenylation Element Binding Protein

DNA

Deoxyribonucleic Acid

eEF2

Eukaryotic Elongation Factor 2

ECM

Extracellular Matrix

eIF3H

Eukaryotic Initiation Factor 3H

eIF4E

Eukaryotic Initiation Factor 4E

eIF4G

Eukaryotic Initiation Factor 4G
vi

EMSA

Electrophoretic Mobility Shift Assay

EMT

Epithelial to Mesenchymal Transition

ER

Estrogen Receptor

ESE

Exon Splicing Enhancer

ESS

Exon Splicing Silencer

FAK

Focal Adhesion Kinase

GTP

Guanosine Triphosphate

HER2

Human Epidermal Growth Factor Receptor 2

hnRNP

Heteronuclear Ribonuclear Protein

hnRNPR

Heteronuclear Ribonuclear Protein R

hnRNPF/H

Heteronuclear Ribonuclear Protein F/H

IHC

Immunohistochemistry

IPA

Ingenuity Pathway Analysis

IRES

Internal Ribosome Entry Site

ITAF

IRES Trans-acting Factor

MSL

Mesenchymal Stem-like

mRNA

Messenger RNA

NGS

Next Generation Sequencing

NMD

Nonsense-mediated decay

PCR

Polymerase Chain Reaction

PIC

Pre-Initiation Complex

Pol II

RNA Polymerase II

PR

Progesterone Receptor

vii

PTM

Post Translational Modification

RBD

RNA Binding Domain

RNA

Ribonucleic Acid

RNP

Ribonucleoprotein

RRM

RNA Recognition Motif

RS

Arginine/Serine-Rich Domain

RT-PCR

Reverse Transcription Polymerase Chain Reaction

SBAP

Streptavidin Biotin Affinity Purification

SR

Serine/Arginine-Rich Protein

SRSF3

Serine/Arginine Splicing Factor 3

ss

Splice Site

TCGA

The Cancer Genome Atlas

TNBC

Triple-Negative Breast Cancer

viii

ABSTRACT
Breast cancer is the second leading cause of cancer-related deaths for women in
the U.S. Although the overall 5-year survival rate for breast cancer is 90%, this rate
drops substantially for triple-negative breast cancer (TNBC) due to its high metastatic
potential. Furthermore, there is a lack of targeted therapeutics for TNBC, and clinical
trials have been largely unsuccessful. These characteristics validate the need for
identifying novel therapeutic targets for the treatment of TNBC. The study of alternative
splicing (AS) has emerged as a powerful tool to elucidate the molecular underpinnings
driving cancer.
Our lab has identified cytoplasmic polyadenylation element-binding protein 2
(CPEB2), which has two main isoforms, CPEB2A and CPEB2B, which differ via the
inclusion/exclusion of exon four in the mature mRNA transcript. These two isoforms
have opposing functions as translational regulators of mRNA species implicated in
metastatic progression. A shift in the spicing ratio favoring an increase in CPEB2B and
a reduction in CPEB2A resulted in increased translation of HIF1α and TWIST1 mRNA,
transcription factors important in the regulation of the hypoxic response and epithelialto-mesenchymal (EMT) pathways and contributed to the acquisition of anoikis
resistance (AnR) and metastasis in TNBC cells in vivo.
Increased levels of serine/arginine-rich factor 3 (SRSF3), an AS regulator, were
identified in TNBC AnR cells. SRSF3 was also determined to be the trans-splicing factor
responsible for regulating the inclusion/exclusion of exon four of CPEB2 by binding to a
ix

consensus sequence within exon four. Mutation of the SRSF3 consensus sequence in
exon four of CPEB2 ablated SRSF3 binding resulting in decreased inclusion of exon
four. A minigene construct investigation of the SRSF3/CPEB2 exon four alternative
splicing axis indicated that downregulation of SRSF3 via siRNA resulted in a CPEB2
alternative splicing ratio shift favoring the production of CPEB2A (exon for exclusion).
However, in the siSRSF3 CPEB2 mutant minigene, the ratio shift was ablated.
Furthermore, siRNA targeting SRSF3 decreased CPEB2B (exon four inclusion) and
reduced AnR and survival in TNBC, which was “rescued” by the ectopic expression
CPEB2B. Ultimately, these studies demonstrate the importance of CPEB2 AS via the
trans-splicing factor SRSF3 in the acquisition of AnR and metastasis in TNBC.
We also propose a mechanism of HIF1 and TWIST1 translational regulation via
CPEB2A and CPEB2B. We determined that the CPEB2A isoform bound to the CPE
sites located in HIF1 and TWIST1 3'UTR mRNA and interacted with known
polyadenylation complex proteins. Similarly, we found CPEB2B associated with
polyadenylation complex proteins, albeit a weaker interaction, but did not bind CPE
sites in HIF1 and TWIST1 3'UTR mRNA. We also found that CPEB2A and CPEB2B
localize to both the nucleus and cytoplasm. Furthermore, we identified novel protein
interactions for CPEB2B, specifically exon four, which is absent in the CPEB2A
transcript. CPEB2B was shown to interact with proteins, specifically, the translation
invitation factor eIF3H and heteronuclear-ribonuclear proteins hnRNPR and hnRNPF/H,
which have been identified as IRES trans-acting factors (ITAFs) important in capindependent translational activation of mRNAs in cellular stress events. Interestingly,
we also identified a strong interaction between CPEB2A and CPEB2B proteins

x

suggesting a potential connection between the CPEB2 alternative splicing regulation
and translational activation/inhibition of HIF1 and TWIST1. These novel interactions
have never been described and provide evidence that alternative splicing inducing a
ratio shift of CPEB2A to CPEB2B proteins results in translational activation of HIF1
and TWIST1 mRNA through an IRES-mediated cap-independent translational
mechanism promoting the acquisition AnR and the metastatic phenotype in TNBC.
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CHAPTER ONE: INTRODUCTION

Alternative mRNA splicing
According to the central dogma of molecular biology, deoxyribonucleic acid
(DNA) is transcribed to ribonucleic acid (RNA), which is then translated into a
polypeptide chain of amino acids called protein. Proteins are responsible for carrying
out a host of diverse cellular functions. It is estimated that the proteome consists of well
over 150,000 unique proteins [1]. Remarkably, this extensive proteome is produced
from the human genome, consisting of only 20,000 genes. The reason that the cell can
produce the extensive proteome from a smaller genome is partly due to a molecular
process known as alternative RNA splicing (AS) [2].
Alternative RNA splicing is a highly regulated molecular process in which
precursor-mRNA is modified to produce the mature mRNA transcript. This modification
is accomplished by excising nucleic acid sequences termed (introns) and joining
together remaining nucleic acid sequences, termed exons via a covalent
phosphodiester linkage in a process called mRNA splicing [3]. Initially discovered by
Phillip Sharp and Richard Roberts in 1977, this process is called splicing because it
resembles the strategy through which a movie editor would cut and splice together film
to produce the final edited version of a movie [4].
Since its discovery, research focused towards understanding AS regulation has
led to many novel findings. It is now known that approximately ninety-five percent of all
genes in the human gene undergo the AS process to produce the mature mRNA
1

transcript. Furthermore, in addition to constitutive splicing, different variations of AS
have been discovered. One such example involves the inclusion or exclusion of exons.
In this AS variation, an exon may be included "spliced in" or excluded "spliced out,"
adding to the potential of multiple proteins being produced by a single gene [5]. By
modulating final mRNA transcripts through the AS mechanism, the cell can adjust the
proteome in response to ever-fluctuating cellular demands ensuring cellular
homeostasis. Dysregulation of this crucial process can lead to a plethora of diseases,
including cancer. Small changes in AS (dysregulation) can have enormous
consequences on the proteome, resulting in significant alterations in cellular signaling
pathways and is often a process cancer cells use to their advantage. Numerous cellular
pathways essential for cancer growth and development may become hyper- or
hypoactive when dysregulation of AS occurs [6]. Some examples of these include
angiogenesis, anoikis resistance, apoptosis resistance, cell proliferation, and cell
migration.

Alternative Splicing Mechanism and Regulation
The molecular process of alternative splicing co-occurs with transcription. This is
accomplished via direct interaction of the translational complex with components of the
spliceosome. The transcriptional complex which is responsible for the process of preRNA splicing is a muti-megaDalton collection of ribonucleoproteins (RNPs) termed the
spliceosome [7]. This complex catalyzes the removal of introns from newly synthesized
pre-mRNA transcripts by RNA polymerase II (Pol II). The spliceosome consists of five
major components, each containing a distinct collection of small nuclear RNAs
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(snRNA). In conjunction with specific RNPs, these snRNAs form the basis of uridinerich small nuclear ribonucleoprotein particles (snRNPs) [8]. For each splicing event, the
assembly of the snRNPs occurs in an ordered and sequential manner and in
conjunction with an extensive network of associated proteins, totaling over three
hundred, to form the spliceosome complex and interacting with specific consensus RNA
cis-elements in the growing pre-mRNA molecule [9].
The process of pre-mRNA maturation is tightly regulated and is dependent on
specific cellular stimuli associated with shifts in physiological states [10]. For most
genes, the synthesis of pre-mRNA is carried out by Pol II, beginning in the promoter
region of the gene. The transcription process resembles a coordinated dance as
numerous transcription factor proteins assemble at the promoter region, forming the
preinitiation complex and ultimately recruiting Pol II. After assembly at the promoter
region, pre-mRNA transcription proceeds as the complex encounters a transcription
start site. Immediately upon the start of transcription, the pre-mRNA is stabilized via a
modification at the 5' end in which a 7-methylguanosine cap is added. In addition to
stabilizing the growing pre-mRNA, the newly added cap also prevents the pre-mRNA
from exonuclease activity [11].
The mechanism of pre-mRNA splicing is enhanced through direct interaction with
the cap-binding complex (U4/U6-U5 tri-snRNP) at the 5' intron site. The first step in the
splice site selection involves the recognition of three conserved sequences near the
exon/intron conjunction by the spliceosome. U1 snRNP binds to the pre-mRNA at the
donor (5’ splice site, ss). The 3' splice site contains an adenine nucleotide also known
as the branch site (BS) and is located just upstream of a variable-length of
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polypyrimidines (polypyrimidine tract). The branch site (BS) is vital to the formation of
the lariat structure during splicing [12].
Additional cis-elements located within both intronic and exonic regions can
promote the inclusion or exclusion of exon and introns in multiple combinations,
promoting significant isoform diversity. Therefore, these cis-elements can contribute to
a variety of isoform variations, including constitutive splicing, selection of competing
spicing sites, and can perform tissue-specific splicing. The mechanism of action for ciselements within the intronic and exonic regions is to facilitate binding of spliceosome
components and thereby initiate/block the splicing program [13]. Exon splicing
enhancers (ESEs) and intron splicing enhancers (ISEs) reside in the exon and introns,
respectively, and promote the inclusion of exons or introns. Exon splicing silencers
(ESS) and intron splicing silencers (ISS) also reside within exon and introns,
respectively, promoting exonic or intronic splicing. The RNA cis-elements promote the
recruitment of non-spliceosome RNA trans-acting factors, which regulate the
mechanism of exon/intron inclusion-exclusion. These cis-elements have been
described as crucial for splice site selection [14].
Although alternative splicing regulation is not fully understood, spice site
selection is regulated by the interaction of cis-elements with trans-acting splicing factors
(trans-factors). These trans-acting factors include serine/arginine (SR)-rich proteins,
heteronuclear ribonuclear proteins (hnRNPs), among others. These trans-acting splice
factors bind to the ESE/ISE or ESS/ISS cis-elements within pre-mRNA and regulate
exon/intron exclusion or inclusion. SR proteins typically bind to ESE cis-elements and
allow spliceosome complex members to bind to 3' and 5' splice sites allowing for the
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inclusion of the exon [15]. Conversely, hnRNPs typically bind ESS cis-elements and
inhibit spliceosome complex members from interacting with 3' and 5' splice sites, usually
resulting in exon exclusion. In order to elicit their specific function, these proteins
contain unique RNA recognition motifs (RRMs), which include quasi and pseudo-RRM
variants, serine/arginine-rich (RS) domains, zinc finger, and K homology (KH) domains
[16]. The domains of the proteins are usually arranged as tandem repeats. In this
manner, splicing factors can recognize different RNAs with varying specificity and
variability. Additionally, the potential for binding of these trans-factors to cis-elements
contained within pre-mRNA is highly dependent upon the presence or absence of posttranslational modifications [17].

Serine/Arginine-Rich Splicing Factor Proteins
Serine/Arginine-rich (SR) proteins are RNA-binding proteins that function as
facilitators of spliceosome assembly, and are required to modulate pre-mRNA
alternative processing, and have a role in regulating the fate of cytoplasmic mRNA. The
SR-protein family consists of twelve family members [18] all of whom consist of one or
two RRM domains in their n-terminal RNA binding domain (RBD). They also contain
the characteristic namesake sequences of arginine and serine dipeptides located in
their arginine/serine (RS) domain closer to the C-terminus. SR proteins are
multifunctional and have been shown to be important regulators of transcription,
alternative splicing, and translation. SR proteins link these pathways via interactions
with Pol II, the spliceosome, and binding mature RNA in the cytoplasm [19]. These
interactions are controlled by the phosphorylation status of serine residues in the RS
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domain, ranging from non-phosphorylated to hyper-phosphorylation. This mechanism of
post-translational modification is highly regulated and allows for stability, RNA binding
specificity, and also enhances specific protein-protein interactions in the spliceosome
formation process [20].
Although it is known that SR proteins regulate AS through interactions and
recruitment of the spliceosome to RNA binding sites, a universal mechanism for SR
proteins is as yet undescribed. This may be attributed to the pleiotropic functional
nature of these proteins in cellular processes. In addition to their role in regulating
alternative splicing, SR proteins have been implicated as functional contributors to a
plethora of cellular processes such as chromatin interactions and cross-regulatory
feedback of non-coding RNA (ncRNA) [21]. Since SR proteins are a crucial regulators
of AS and are multifunctional RNA binding factors, aberrant expression of SR proteins
can lead to numerous disease states [22]. This is partly due to SR proteins' vital role in
regulating the transcriptome via RNA splicing regulation. Indeed, multiple laboratory
groups have noted aberrant expression of SR proteins in multiple cancer types [23].

Cytoplasmic Polyadenylation Element Binding Protein 2 (CPEB2)
Cytoplasmic polyadenylation element-binding protein 2 (CPEB2) belongs to the
CPEB family of proteins that mediate polyadenylation of mRNA targets in the
cytoplasm. CPEB proteins recruit cytoplasmic polyadenylation machinery and regulate
the repression and activation of translation of targeted mRNA [24]. The CPEB protein
family consists of four family members (1-4). CPEB proteins are divided into two
categories based on protein sequence alignment similarity [25]. CPEB1 is the most
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distinct of the CPEB family members, whereas CPEB2, CPEB3, and CPEB4 are closely
related. An initial examination of CPEB2-4 via SELEX analysis indicated that CPEB2-4
proteins interact with different RNA cis-regulatory elements than the CPE sequence
identified for CPEB1 [26]. However, further studies revealed that the CPEB2-4 proteins
will bind the CPE consensus sequence, but these interactions are weaker than the
CPEB1 interaction [27]. In other studies, CPEB3 was also shown to bind the CPE
consensus sequence [28]. The first of the CPEB family members to be discovered and
characterized was CPEB1. In Xenopus laevis oocytes, CPEB1 was identified as a
translational regulator of mRNA species important in oocyte maturation, embryonic and
neuronal development [29]. CPEB2-4 regulate translation of mRNAs important in
memory, learning and stress response pathways [30]. Since their initial discovery,
CPEB proteins have been described as important regulators of translation in multiple
cell types.
Structurally, all CPEB proteins contain three regions: an N-terminal domain
characterized as intrinsically disordered, highly structured c-terminal domains consisting
of two RNA recognition motifs (RRMs) in close proximity to each other and a cysteinehistidine-rich region that resembles a zinc finger at the end of the C-terminus. The
RRMs of CPEB proteins bind a consensus cytoplasmic polyadenylation element (CPE)
sequence, the most common of which is UUUUUAU, located in the 3' untranslated
regions (UTR) of mature mRNA transcripts [31]. There is debate as to the manner in
which the RRMs of CPEB proteins bind the CPEs of mRNA. Traditionally, the RRMs of
CPEBs were thought to individually bind CPEs in mRNA UTRs; however, there is
evidence that the RRMs may bind to a single CPE site in a manner termed "fly-trap"
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[32]. Interestingly, evidence suggests that CPEB proteins, specifically CPEB1 and
CPEB4, bind the CPEs of target mRNAs in the nucleus. The CPEB/mRNA complex is
then exported to the cytoplasm [33]. In this manner, CPEB proteins can exhibit tight
control of the expression of mRNAs which are crucial to stress responses.
As previously mentioned, the N-terminal end of CPEB proteins is characterized
as intrinsically disordered. The N-terminal domain sequences of CPEB proteins vary
greatly amongst family members. In CPEB1, the N-terminal region was shown to bind
to proteins that belong to the polyadenylation complex, specifically GLD2 and PARN, as
well as the cap-binding initiation factor eIF4E [34]. In this manner, CPEB1 regulates the
translation of target mRNA. Specifically, Richter and colleges showed that CPEB1
binds to the 3'UTR CPE site in mRNA, interacts with the polyadenylation complex
proteins GLD2 and PARN [35]. PARN, a deadenylating enzyme, outcompetes GLD2, a
poly(A) polymerase, therefore inhibiting the polyadenylation of the mRNA. CPEB1 also
interacts with eIF4E, a cap-binding protein, ultimately inhibiting the eIF4E/eIF4G
interaction from recruiting the 43s preinitiation complex and halting translation initiation.
Upon phosphorylation of CPEB1 via Aurora kinase, CPEB1 undergoes a conformational
change and disassociation with PARN. This allows for polyadenylation of the mRNA by
GLD2. Furthermore, this conformational change releases eIF4E, allowing interaction
with eIF4G, and recruits the 43s preinitiation complex to the 5'cap initiating translation
[36]. However, as mentioned earlier, the mechanism for regulating mRNA translation by
the CPEB (2-4) family members differ from CPEB1 due, in part, to CPEB (2-4) proteins
missing the Aurora kinase phosphorylation site in the N-terminal domain [37].
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Although translational regulation of mRNA by CPEB2 differs for CPEB1, some
progress towards understanding its mechanism has been reported. Chen and
colleagues reported that CPEB2 inhibits translation of hypoxia-inducible factor onealpha (HIF1) by binding to its 3'CPE region in conjunction with binding to the eEF2
elongation factor in Neuro 2A (N2A) murine cells. Upon oxidative stress, a GTP/GDP
reaction releases eEF2, and the ribosome is able to continue translation [38]. A
mechanism of translational regulation by CPEB2 was also described for Twist Family
BHLH Transcription Factor 1 (TWIST1) in MCF-10A non-malignant breast epithelial
cells by Nairisgami and colleagues. They reported a mechanism in which CPEB2 and
CPEB1 regulate TWIST1 translation by binding to CPE sites, of which there are two,
within the TWIST1 3'UTR and allowing polyadenylation of TWIST1 mRNA. The binding
of both CPE sites allows for the inclusion of miRNA regulatory binding sites in the
3'UTR, leading to reduced TWIST1 protein translation [39].

Epithelial-Mesenchymal Transition
A characteristic of epithelial cells is that they maintain apical-basal polarity,
including contact with adjacent cells. The contact with adjacent cells is accomplished
through tight junctions, desmosomes, and adherens junctions [40]. On the other hand,
characteristics of mesenchymal cells include separation from surrounding cells, a lack
of basal lamina, which separates them from adjacent tissue, and they do not contain
distinctive apical-basolateral polarity that is characteristic of epithelial cells [41].
The epithelial-mesenchymal transition (EMT) is generally defined as the
acquisition of mesenchymal characteristics by epithelial cells. This process occurs
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naturally in several biological processes such as embryonic development and in tissue
regeneration; however, an aberrant form of EMT occurs in cancer progression [42]. As
a contributor to cancer progression, EMT can promote the malignant phenotype in
primary solid tumors, allowing heightened invasiveness and metastasis [43]. However,
secondary tumor histological characteristics tend to resemble that of the primary tumor
[44]. The histological feature that connects the primary and secondary tumors is the
EMT.
Furthermore, the reversibility of EMT has been demonstrated in mesenchymal
tumor types and has been termed mesenchymal-epithelial transition (MET) [45]. The
molecular events contributing to the advent of EMT are a loss of adherent junctions
coinciding with the downregulation of cytokeratin and E-cadherin and increases in
mesenchymal associated markers such as N-cadherin, vimentin, and fibronectin [46].
Furthermore, EMT promotes the increase in the invasive phenotype and is associated
with anoikis resistance.
In cancer, EMT is a common mechanism driving the invasive and metastatic
progression of tumors. Indeed, a role for EMT in tumorigenesis has been reported in
numerous cancer types, including lung, prostate, liver, pancreatic, breast, and non-small
cell lung cancers [47]. Widespread changes in ECM-related proteins, including
collagens, integrins, and metalloprotease, which are activated by signaling cascades in
Ras, Wnt/β-catenin, and Src pathways are the initial step in EMT [48]. Dismantling of
the basement membrane by tumor cells at the stromal interface combined with
activation of matrix contribute to the invasive phenotype in cancer. The process allows
for increased cell motility and angiogenesis, setting the stage for systemic escape. For
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the cell to induce motility during EMT, cytoskeletal rearrangements are necessary. This
is accomplished through the upregulation of Cofilin 1 (CFL1). CFL1, in turn, binds Factin filaments, and regulation of cytoskeleton dynamics is achieved [49]. The
transcription factor TGFβ1, which is a known activator of EMT, induces CFL1 and
regulates the assembly/disassembly of microfilaments necessary for cell motility [50].
vimentin is another filament protein essential in the EMT process which is upregulated
in tumor cells. Vimentin acts to stabilize collagen RNAs which expression contribute to
high collagen levels, a typical characteristic of mesenchymal cells [51]. Collectively, the
shift towards the increased expression of these key proteins drives the migratory and
invasive phenotype associated with EMT.
The activation of EMT, and the orchestrated increase in the proteins responsible,
including the phenotypic changes, are dependent upon a plethora of activated
transcription factors. One such transcription factor critical to the EMT process is
TWIST1. Typically, TWIST1 orchestrates the mesoderm formation in embryotic
maturation [52]. However, in EMT, TWIST1 regulates a necessary process termed
"cadherin switching," in which E-cadherin is repressed, and N-cadherin is activated [53].
Notably, increased expression of TWIST1 is reported in numerous cancers and invasive
cell lines. The high levels of TWIST1 are also associated with an increase in the
aggressive phenotype, reduced survival, and higher incidences of recurrence [54].
Another important transcription factor that contributes to EMT is the hypoxiainducible factor (HIF). The tumor microenvironment typically consists of hypoxic
conditions because the aggressive growth of tumor cells often outpace the supply of
oxygen available in the blood supply. To overcome the hypoxic conditions, the cell
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responds with HIF activation. Activation of HIF is accomplished through the
dimerization of the HIF1 and HIF1β subunits. The combined subunits create an
activated transcription factor that targets hypoxia-related genes, regulating numerous
pathways, including survival, motility, and angiogenesis [55]. The hypoxic response
also contributes to the activation of EMT and the metastatic cascade in numerous
cancers, including ovarian, breast, and glioblastoma [56].

Anoikis Resistance
Perhaps the deadliest clinic-pathological phenotype in breast cancer is
metastasis. It is estimated that ninety percent of all cancer-related deaths are attributed
to metastasis [57]. An essential precursor in the early stages of metastatic
transformation is the acquisition of Anoikis resistance (AnR). Typically, cells will
undergo apoptosis after they lose contact with their extracellular matrix or their
neighboring cells. This cell death process is called "anoikis," a term coined in 1994 by
Frisch and Francis and means the "state of being without a home" [58]. Tumor cells
that acquire malignant potential have developed mechanisms to resist anoikis and
thereby survive after detachment from the primary tumor. Anoikis-resistant cells also
demonstrate a hyper-activation of mitogenic signaling and EMT [59]. Anoikis regulation
is dependent upon crosstalk between integrin-ECM attachment and signaling of growth
factors critical to EMT. The role of integrins is to act as intermediaries in signaling
cascades that link the extracellular matrix with the intercellular network through the
combining of integrin-activated signaling such as focal adhesion kinase (FAK), ERK1/2,
MAPK, and phosphatidylinositol-3-kinase (PI3K) [60]. The survival of cancer cells
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during the acquisition of AnR is also dependent upon changes to the integrin profile. As
a promoter of apoptosis, integrin αvβ5 is downregulated while an increase in the
expression of αvβ6 activates pathways such as PI3K-AKT, which promote survival [61].
As an additional level of AnR regulation, autophagy, a process characterized by
the degradation of proteins and organelles via lysosomes in response to cellar stresses
and promoting survival, can mitigate AnR [62]. Pre-metastatic migrating tumor cells
which demonstrate autophagy can delay apoptotic activation. Activation of this
autophagic pathway allows temporary protection to the tumor cell, during which
circulating tumor cells happen upon their destination and activates ECM reattachment
[63]. Although tumors shed a large number of cells, only those that have acquired AnR
and molecular plasticity will survive their hostile detachment and settle at distant sites
and reactivate growth [64].

Cap-Independent mRNA translation
The cap-dependent mechanism of translation is the most common form of mRNA
translation in eukaryotes. During transcription, an m7G (7-methyl guanosine) cap is
added to the 5' end of the pre-mRNA [65]. During cap-dependent translation initiation,
the m7G cap provides a recognition site for eukaryotic initiation factor 4E (eIF4E). This
initiation factor is part of a larger eIF4F complex consisting of several initiation factors,
including eIF4E, eIF4G, and eIF4A. The binding of eIF4E, and subsequently the eIF4F
complex, facilitates the recruitment of another large complex, namely the preassembled 43S preinitiation complex (PIC) [66]. Components of the 43S PIC complex
include the 40S ribosomal subunit, the initiation factors eIF1, eIF1A, eIF3, and eIF5 [67].
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Additionally, the eIF4F complex recruits the eIF2/Met-tRNAi/GTP ternary complex.
Upon assembly of the complexes, the 43S PIC complex scans the 5' untranslated
region (UTR) of the mRNA until it encounters the start codon and recruitment of the 60S
large ribosomal subunit is initiated. Combined, the 43 PIC complex and the 60S larger
ribosomal subunit from the 80S ribosome and peptide synthesis occurs [68].
Some cellular conditions are not conducive to the cap-dependent mechanism of
mRNA translation. One such example is during viral infection, as a variety of viral
mRNAs are robustly translated by the host cell despite the absence of a 5' m7G cap
structure [69]. In these instances, the alternative mechanism known as capindependent translation can allow for translation using what is known as internal
ribosome entry site (IRESs). Genes that allow the cap-independent translation are
typically involved in cellular stress or viral infection, which suggests a role for IRESmediated cap-independent translation under these cellular events [70].
Internal ribosome entry sites were first discovered in viruses of the Picornaviridae
family, including the encephalomyocarditis virus and poliovirus (PV) [71]. Future
discoveries of IRESs were later found in pathogenic viruses such as the hepatitis C
virus (HCV) and human immunodeficiency virus (HIV) [72]. Many of these viral IRESs
contain both similar secondary structures and can mechanisms of translation. However,
the functional activity of these IRESs is often dependent upon other factors called IREStransacting factors (ITAFs) [73]. The IRES sites are typically located in the 5' UTR of
mRNA, downstream from the 5' cap structure. Although the mechanism of translational
initiation is unclear, there is evidence that IRESs whose secondary structures differ
require different ITAFs to associate with the 40s ribosomal subunit [74]. In general, the
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activation of IRES cap-independent translation forgoes the formation of the eIF4E capbinding and PIC recruitment to the 5' m7G cap allowing for the recruitment of the 40s
ribosomal subunit to the IRES site by ITAFs, therefore, initiating peptide synthesis [75].
In eukaryotes, IRESs were also found in cellular mRNA. In fact, it is now
estimated that ten percent of cellular mRNAs contain IRES sites [76]. Many of these
mRNAs are essential in stress response pathways such as mitosis, hypoxia, and
apoptosis [77]. Compared to viral IRESs, cellular IRESs have fewer RNA structures
and appear to contain very little sequence conservation. Cellular IRESs are typically
divided into two types depending on the mechanism in which the ribosome is recruited.
The first type, type I, ribosomal interaction is dependent upon ITAFs bound to N-6methadenosine (m6A) and RNA binding motif cis-elements. Type II IRESs differ from
type I because they contain a short cis-element that joins the 18S rRNA for ribosome
recruitment [78].
Almost all known cellular IRESs are dependent upon the assistance of numerous
ITAFs, which are typically RNA binding proteins, for recruitment of ribosomes and the
initiation of translation. Most ITAF proteins are either nuclear or both nuclear and
cytoplasmic shuttling proteins, which suggests that ITAFs engage in crosstalk between
the transcription and translation processes [79]. An example of one such ITAF is the
polypyrimidine tract-binding protein (PTB) which promotes the activity of numerous
cellular IRESs. Functionally, the PTB protein promotes the ideas of crosstalk by ITAFs
in the transcription and translation process as PTB is described as a regulator of mRNA
splicing and transport [80]. The mechanism in which describe how ITAFs facilitate capindependent IRES translation remains unclear. There is evidence that ITAFs may
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function in an RNA chaperone capacity, remodeling the structure around the IRES,
which enhances the ability of ribosomes to bind to the IRES [81].
It is known that under numerous cellular conditions such as hypoxia, heat shock,
mitosis, DNA damage, nutrient depletion, and apoptosis, global translation is
downregulated. These cellular conditions also coincide with characteristics of tumor
progression, such as metastasis. However, tumors also need the active translation of
specific proteins to cope with stresses associated with tumor progression. Many of the
precursor mRNAs that code for these proteins contain IRESs, which suggest that capindependent IRES-mediated translation plays a role in tumor progression. Indeed, there
is evidence to support this theory as IRES-mediated translation was shown to promote
the survival of tumor cells in inflammatory breast cancer and ovarian cancer [82]. In a
3D ovarian cell culture, treatment with a PI3K/mTOR inhibitor (downregulates capdependent peptide synthesis) leads to high cell death via apoptosis. However, cells that
exhibited resistance to the inhibitor were shown to overexpress IRES-containing
proteins [83]. These studies demonstrate that cap-independent IRES translation is
crucial for tumor progression.

Triple-Negative Breast Cancer (TNBC)
Breast cancer is currently the most diagnosed cancer in women accounting for
more than 1:8 new cancer diagnoses each year [84]. It is also currently the second
leading cause of cancer-related deaths in women [85]. In 2021, there were roughly
330,000 cases and over 43,000 deaths in the US [86]. In 2020, there were
approximately 2.3 million diagnosed cases of breast cancer and over 500,000 deaths
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from this disease [87]. Triple-negative breast cancer (TNBC) is a highly aggressive and
deadly form of breast cancer. TNBC accounts for roughly 15% of all diagnosed breast
cancer cases each year. Also, the five-year survival rate of TNBC is substantially lower
than all other types of receptor-positive breast cancers [88]. TNBC is also more
common in women under forty and African American women [89]. TNBC also has
higher growth and metastatic potential and a higher incidence of recurrence and thus
poorer outcomes compared to receptor-positive subsets [90].
The term "triple-negative" refers to the surface receptor expression pattern of the
cancer cells. It indicates that the cells lack the estrogen receptor (ER), progesterone
receptor (PR), and epidermal growth factor receptor 2 (ERBB2, commonly referred to as
HER2) [91]. TNBC belongs to the basal-like subclass of breast cancers characterized
by an expression profile similar to that of myoepithelial normal mammary cells. Basal
tumors frequently assimilate to triple-negative (TN) breast cancers. They display
epidemiological and pathological features distinct from other subtypes. Furthermore,
another subset of the basal classification is termed "claudin-low" [92]. Claudins are
tetra-span transmembrane proteins of tight junctions. They are important in determining
the barrier properties of cell-cell contact existing between the plasma membranes of two
neighboring cells [93]. Compared to hormone receptor-positive breast cancer subtypes,
TNBC displays considerable genetic complexity and tumor heterogeneity, leading some
to suggest that "triple-negative breast cancers" is a more suitable name [94].
Genetically, TNBC is typically heterozygotes for P53, although there is evidence
that advanced stages of the disease are p53 null [95]. About 70% of the triple-negative
breast cancer cases are BRCA1 null [96]. Since TNBC lacks traditional
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chemotherapeutic targets, treatment for TNBC has mainly been unsuccessful, leading
to poorer outcomes. Although some chemotherapeutics, such as taxens, platinum
agents, and PDL1 inhibitors, show initial success, TNBC tends to acquire resistance
leading to the lowest overall five-year survival rate of all breast cancer subtypes [97].
Furthermore, TNBC's high propensity towards metastasis, in conjunction with lacking
known therapeutic targets, makes the discovery of novel treatment options imperative.

Alternative mRNA Splicing of CPEB2 in TNBC
Although the metastatic potential of TNBC provides unique treatment challenges,
it can also offer opportunities to identify novel therapeutic targets since metastasis
requires significant transcriptome alterations to drive the drastic phenotypic changes
[98]. The transcriptome alterations influencing TNBC progression result in shifts in
alternative pre-RNA splicing (AS). Changes in AS alter the transcriptome profile leading
to significant changes in the proteome. Alternative splicing of CPEB2 produces two
main isoforms: CPEB2A (lacking exon 4) is constitutively expressed, is anti-neoplastic,
and has been shown to inhibit translation of hypoxia-inducible factor 1-alpha (HIF1)
and twist related protein 1 (TWIST1), and CPEB2B (exon 4 included) which activates
the translation of HIF1 and TWIST1 mRNA species driving anoikis resistance (AnR)
and metastasis [99]. The studies presented herein are meant to elucidate critical
aspects of AS dysregulation responsible for the aggressive metastatic potential of
TNBC in the hope of furthering the identification and development of novel strategies
targeting TNBC progression. Elucidation of the effects of AS dysregulation, and
mechanisms governing such, in conjunction with continued marked advances in modern
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medicine, provide the measured optimism towards improving TNBC treatment and
outcomes.

Hypothesis and Specific Aims
The research presented in this dissertation two important scientific questions.
First, what RNA cis and trans-splicing regulatory elements are responsible for regulating
CPEB2 alternative splicing? Secondly, by what mechanism do the CPEB2A/B proteins
regulate the translation of targeted mRNA species? Two hypotheses were examined to
investigate these questions. For the first question, our studies investigated whether
SRSF3 is the trans-splicing factor responsible for modulating the expression of CPEB2B
via binding the pre-mRNA exon splicing enhancer cis-element located in exon four of
CPEB2B. To address the second question, this research proposed that CPEB2A and
CPEB2B regulate translation of mRNAs via interaction with CPE binding sites within the
3'UTR of mRNA and recruitment of polyadenylation complex proteins. The mechanism
of increased regulation by CPEB2B results in novel interactions of exon four with ITAF
promoting cap-independent IRES-mediated peptide synthesis.
There are two specific aims contained in this dissertation. The first specific aim
attempts to characterize the mechanism for the inclusion of exon four in the CPEB2B
isoform via splicing regulation by SRSF3. The second is to elucidate the mechanism of
translational control of mRNA by the CPEB2A and CPEB2B isoforms. A rigorous effort
has been made to determine well-described connections among the proposed
hypotheses and specific aims to reveal a prescribed mechanism influencing the
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alternative splicing of CPEB2 and its importance in biological events in TNBC
progression.
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CHAPTER 2: SERINE/ARGININE-RICH SPLICING FACTOR 3 MODULATES
ALTERNATIVE SPLICING OF CYTOPLASMIC POLYADENYLATION ELEMENT
BINDING PROTEIN 2

Abstract
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with
a low 5-year survival rate and high metastatic rate. Our laboratory has elucidated a role
for which the alternative RNA splicing (AS) of cytoplasmic polyadenylation elementbinding protein 2 (CPEB2) contributes to the metastatic phenotype in TNBC. The
alternative spliced variants of CPEB2 differ via the inclusion/exclusion of exon four. In
these studies, the mechanism governing the regulation of exon four inclusion/exclusion
was investigated. Specifically, we found that the RNA trans-acting factor serinearginine splicing factor 3 (SRSF3) directly interacted with exon four of CPEB2. We also
identified a consensus sequence for SRSF3 in exon four, which ablated SRSF3 exon
four interaction when mutated. Increased expression of SRSF3 protein was also
determined in TNBC in conjunction with the acquisition of anoikis resistance (AnR).
This finding also correlated with a reduced CPEB2A/B expression profile favoring an
increase in the CPEB2B isoform. Additionally, SRSF3 knock-down via siRNA resulted
in decreased exon four inclusion, namely an increase in the CPEB2A isoform,
corresponding to a decrease in CPEB2B (exon4 inclusion). These findings were
consistent with siSRSF3 treatment in a wild-type CPEB2 exon four minigene and a
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mutant CPEB2 minigene containing an ablated SRSF3 RNA cis-element. Also,
downregulation of SRSF3 resulted in reacquisition of anoikis sensitivity in TNBC and
ectopic expression of CPEB2B "rescued" this phenotype. Notably, The Cancer Genome
Atlas (TCGA) analysis indicated a positive correlation between SRSF3 expression and
reduced CPEB2A/B ratios in the most aggressive forms of breast cancer. These
findings suggest that SRSF3 is at least partially responsible for regulating CPEB2 AS
and promoting an aggressive phenotype in TNBC.

Introduction
TNBC is one of the four major breast cancer subtypes and is characterized
histologically based upon its lack of the epidermal growth factor receptor 2 (HER2),
estrogen receptor (ER), and progesterone receptor (PR) [100]. Compared to the breast
cancers subclass, which express these hormone receptors, TNBC exhibits heightened
genetic complexity and tumor heterogenicity, rendering treatment with targeted
therapies ineffective [101]. Traditional treatment options for TNBC include neoadjuvant
chemotherapy and surgery, which initially prove relatively successful. However, TNBC
commonly acquires resistance to chemotherapies resulting in the lowest five-year
progression-free and survival rates of all the breast cancer subtypes [102]. This
characteristic, in conjunction with the aggressive nature of TNBC, underlines the
necessity of the discovery of novel targets and therapeutic strategies.
TNBCs characteristic molecular and histological complexity suggests early stage
shifts in gene expression may contribute to the tumorigenic propensity of the cells [103].
Regulatory pathways which can contribute to the genetic alterations promoting breast
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cancer progression include changes in alternative pre-mRNA splicing (AS). While AS is
well documented to promote the expression of cancer-specific variants, alterations in
the proteins which regulate AS, mRNA splicing factors occur on a broad scale in TNBC
[104]. These alterations contribute to the increased complexity of exon assembly during
AS events. Indeed, increased expression of mRNA trans-splicing factors can contribute
to the malignant phenotypes in cancer via altered regulation of downstream AS
pathways [105].
Our lab recently showed that AS of cytoplasmic polyadenylation element-binding
protein 2 (CPEB2) directly regulates TNBC metastasis [106]. Specifically, a splicing
ratio shift favoring increased expression of the CPEB2B isoform, which contains exon
four, contributed anoikis resistance (AnR), detachment-induced cell death, promoting
tumor metastasis to the lung. The pro-neoplastic transformative role for CPEB2B differs
from the CPEB2A variant, which demonstrated reduced tumor growth and metastasis in
TNBC via translational repression of the TWIST1 and HIF1α transcription factors. In
non-tumorigenic breast cancer tissue, the CPEB2A/B isoform ratio is usually high,
favoring the CPEB2A transcript. However, in TNBC, including cells that acquired the
AnR phenotype, the ratio was reduced, coinciding with increased CPEB2B transcription
[107].
Cytoplasmic polyadenylation element-binding protein 2 (CPEB2) belongs to the
CPEB family of proteins that mediate polyadenylation of mRNA targets in the
cytoplasm. The CPEB protein family consists of four family members (1-4). CPEB
proteins are divided into two categories based on protein sequence alignment similarity.
CPEB1 is the most distinct of the CPEB family members, whereas CPEB2, CPEB3, and
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CPEB4 are closely related [108]. Structurally, all CPEB proteins contain three regions.
They have an N-terminal domain characterized as intrinsically disordered, highly
structured c-terminal domains consisting of two RNA recognition motifs (RRMs) in close
proximity to each other and a cysteine-histidine region that resembles a zinc finger
[109]. The RRMs of CPEB proteins bind a consensus cytoplasmic polyadenylation
element (CPE) sequence, the most common of which is UUUUUAU, located in the 3'
untranslated regions (UTR) of mature mRNA transcripts [110]. The most studied and
well described member of the CPEB family of protein is CPEB1 which has been shown
as a translational regulator targeted mRNA species. Specifically, Richter and colleges
showed that CPEB1 binds to the 3'UTR CPE site in mRNA, interacts with the
polyadenylation complex proteins GLD2 and PARN. PARN, a deadenylating enzyme,
outcompetes GLD2, a poly(A) polymerase, therefore inhibiting the polyadenylation of
the mRNA [111]. There is limited research pertaining to the other CPEB family
members; however, CPEB2 has been described as essential for mitotic cell division
[112].
Possible AS regulators which modulate the AS of CPEB2 include the
serine/arginine (SR)-rich protein family of proteins. SR proteins are RNA trans-acting
factors that regulate splice site selection via exon exclusion/inclusion [113]. This is
dependent on the binding affinity of the RNA recognition motif (RRM) and binding
domain contained in the SR protein to mRNA cis-elements, termed exon splicing
enhancers (ESE), located within exons, and mediation of spliceosome assembly [114].
An important and well described member of the SR protein family, SRSF3, has been
reported in increased levels during hypoxic and oxidative stress events [115]. These

24

events are also commonly found in tumors in which trans-splicing mRNA factors can
regulate the AS of genes important in cellular processes such as cell cycle progression
and proliferation [116].
In this study, our laboratory identified an increase in the occurrence of SRSF3
and the CPEB2 variant in TNBC. Our lab has also identified an SRSF3 consensus
binding motif in exon four of CPEB2, in which inclusion promotes the CPEB2B isoform
in TNBC. These findings provide evidence indicating an SRSF3 mediated splicing
event promotes increased CPEB2 isoform expression linked to AnR and metastasis in
TNBC.

Materials and Methods
Cell Culture and Reagents:
MDA-231, MDA-468, and BT549 cells were obtained from ATCC (Manassas, VA)
and maintained in RPMI (Invitrogen). The cell lines were supplemented with 10% fetal
bovine serum (FBS, Invitrogen) and 1% Penicillin / Streptomycin (Invitrogen). Cell lines
were maintained in a 95% air / 5% CO2 incubator at 37°C. Cells were passaged once
every 3-5 days (~90% confluence), and all experiments were performed during the first
12 passages.

Western Blotting:
Total protein (5-10 μg) was electrophoretically separated on 7.5% or 12% SDSpolyacrylamide gels. Samples were transferred electrophoretically to PVDF
membranes, then probed with the appropriate antibody as described previously [117].
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Antibodies were purchased from Cell Signaling with the exception of SRSF3
(ThermoFisher, Clone ID: 7B4).

Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR):
Primer/probe sets were designed for CPEB2A (forward, 5′GTGTTCAGAACAGACAACAATAG-3′; reverse, AATATCGATAAGGGAATTTTCC;
Probe, 5′-CCCTTACAGGATCGAAGTAGAATGTATGACAG-3′) and CPEB2B (forward,
5′-CCTGGTCTATTCTGGATGTTCC-3′; reverse, 5′-ACCCTTACAGGTGAGATCTAGT3′; probe, 5′-TCACTCCAAGATAGTTGGTGCACTGC-3′) and purchased from Integrated
DNA Technologies. PCR was performed as described [117]. cDNA synthesis was
accomplished using the Superscript III kit (Life Technologies) according to the
manufacturer's instructions. Samples were amplified with the Bio-Rad CFX Connect
qPCR machine and then calculated using the standard curve method.

siRNA Treatment and Plasmid Transfection:
All transfections were performed in triplicate with 6-well tissue culture dishes.
Validated Silencer Select siRNA towards SRSF3 (s12732 or s12733) or non-targeting
control (ThermoFisher Scientific) were utilized in this study at 30 nM concentrations and
transfected using Dharmafect 4 transfection reagent (Dharmacon) as described
previously and to manufacturer's specifications. The plasmid transfections were
accomplished using the Effectene system (Qiagen) according to the manufacturer's
instructions and using 0.5 to 1.0 g total DNA per well.
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Anoikis Resistance Assay:
Cells were transfected using the indicated siRNA and DNA plasmid with
Dharmafect Duo transfection reagent (Dharmacon). After 48 hours, the cells were
washed, trypsinized, and added to each well of either standard or polyHEMA-coated 6well tissue culture plates. The cells were incubated for 6 hours, then collected for
analysis via Western blotting.

Competitive Quantitative RT-PCR:
cDNA was synthesized as previously described [118], and then competitive PCR
was performed on the cDNA samples using the following primers: endogenous CPEB2A
or CPEB2B isoform amplification FWD primer 5’-GCAGCAGAGGAACTCCTATAAC-3'
and reverse primer 5’-CAAAGAGTGCATATTCAAACTGTCA-3', minigene specific
CPEB2A or CPEB2B isoform amplification forward primer 5’CAGAACAGACAACAATAGTAATACACTC-3' and reverse primer 5’AGGGGCAAACAACAGATGG-3'. PCR conditions for the endogenous gene
amplification consisted of a denaturing step, 98 C for 30 seconds, followed by 25
cycles of a second denaturing step at 98 C 10 sec., 50 C annealing for 30 sec., 72 C
extension for 1 min., and final extension step at 72 C for 5 mins. Minigene-specific
amplification conditions were identical, and 20 cycles were used. All PCR reactions
were amplified with standard Taq polymerase (New England Biolabs) with products run
on 5% polyacrylamide-TBE and stained with SYBRgold (ThermoFisher Scientific).
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RNA Binding Assays:
Full length Wild-type biotinylated RNA CPEB2 exon sequence (Bi: 5’GTGAGATCTAGTTTGCAGTTGCCAGCTTGGGGCTCAGATTCACTCCAAGATAGTTG
GTGCACTGCAGCCGGAACATCCAGAATAGACCAG-3') or mutant sequence (MUT,
see Fig.1) were incubated with recombinant SRSF3 (lsBio) and RNA-bound proteins
were precipitated as described [118]. Samples were subjected to immunoblotting with
an SRSF3 antibody.

Electrophoretic Mobility Shift Assay:
FITC conjugated full length (Fig.1A) or partial (Fig.1E) wild-type or mutant
CPEB2 RNA sequences were subjected to EMSA as described [118].

Construction of Minigene Plasmids:
Genomic regions of CPEB2 spanning exons 3,4 and 5 were investigated in this
study. The template DNA was amplified from the RPCI-11 HS BAC Clone
(ThermoFisher, Clone ID: 629A7) using two different 1.7 kilobase fragments. PCR
reactions utilized forward and reverse primers in order to amplify the exon 3, intron 3,
exon 4, and partial segment of intron 4 regions with the following sequences 5’AAACGGGCCCTCTAGATTTCCCTAGCCTCTTCTGA-3' and 5’GGAAGGAATGCTAGATGACTAACGGTTTCTCCATA-3'. The second fragment was
amplified with forward and reverse primers targeting a region of intron 4 directly
upstream of exon 5, including all but the last three codons of exon 5. The forward and
reverse PCR primers used consisted of sequences 5’-TCTAGCATTCCTTCCGTCA-3'
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and 5’-TACCGAGCTCGGATCCGGATCATGCTCTGCTCTC-3'. The genomic DNA
fragments were amplified using standard PCR conditions and proofreading Taq
polymerase (Phusion High Fidelity DNA Polymerase, New England Biolabs). The PCR
conditions consisted of a denaturing step of 98 C for 30 seconds followed by 30 cycles,
98 C denaturing for 10 sec., 60 C annealing for 30 seconds, 72 C extension for 30
sec., and final extension step at 72 C for 10 min. Fusion of amplified genomic DNA
material with the pcDNA3.1(-) mammalian vector (Invitrogen) was accomplished using
the In-Fusion HD cloning reaction (Clontech). With each step of PCR amplification and
plasmid generation, CPEB2 minigene sequences were verified by Sanger dideoxy
method (GenScript). The CPEB2 minigene insert was designed retaining the XbaI, and
BamHI restriction sites at the 5' and 3' ends respectively. All of the primers used in
cloning and analysis were synthesized by Integrated DNA Technologies. Site-directed
mutagenesis was performed using the QuikChange II XL Site-Directed Mutagenesis Kit
(Agilent) according to manufacturer's instructions along with primers containing the
mutated CPEB2 ESE with forward and reverse sequences 5’GGTGCACTGCAGCCGGAAGAGTCAGAATAGACCAGGTAGG-3' and 5'CCTACCTGGTCTATTCTGACTCTTCCGGCTGCAGTGCACC-3'.
The CPEB2B-flag plasmid construct was previously reported.

Biostatistics:
Biostatistical analyses were carried out using either SPSS or R. Statistical tests
used include one-way ANOVA/ pooled t-test (in the case of only two samples), ANOVA
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(in the case of multiple samples), and an FDR-adjusted p-value with Tukey HSD post
hoc calculation.

Results
Unbiased Proteomic Analysis Identified SRSF3 Association with Exon four of CPEB2.
Our lab previously reported that AnR acquisition in TNBC required the AS variant
of CPEB2, CPEB2B, which includes exon four in the mature mRNA [119]. This
discovery prompted an investigation into the mechanism which governs exon four
inclusion promoting CPEB2B isoform production. To accomplish this goal, the
employment of electrophoretic mobility shift assays (EMSAs) analysis, using MDA-231
cell extract, was used to investigate protein complexes that associate with exon four of
CPEB. Using an unbiased proteomic approach analyzing complexes that bind exon
four of CPEB2 identified the several RNA trans-acting factors, including SRSF3 and
numerous hnRNP proteins including hnRNPF and hnRNPH1 (Fig. 1A; Table 1). Or
these, SRSF3 was validated by employing an anti-SRSF3 antibody and cross-linking
immunoprecipitation combined with quantitative real-time PCR (Clip-qRT-PCR). The
SRSF3/exon four interaction was observed in MDA-231 parental (Par) and in the MDA231 anoikis resistant (AnR) cells (Fig. 1B). Additionally, increased SRSF3 protein levels
were detected in the TNBC cells, which acquired the AnR phenotype (Fig. 1B).
Crosslinking of total RNA by SRSF3 was seen in both MDA-231 Par and AnR
cells. Additionally, SRSF3 interaction with exon four was seen in both Par and AnR
cells via qRT-PCR, specifically targeting exon four of CPEB2. The SRSF3/exon four
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interaction was significantly increased in the AnR cells (Fig. 1B). Furthermore, SRSF3
protein levels were increased in TNBC AnR cells (Fig. 1B).
Examination of consensus sequences contained in exon four elucidated the
(C/U)(A/C/U)(U/A)(C/A/U)(A/C/U) sequence (Fig. 1C), and to investigate this
association, a streptavidin-biotin affinity purification (SBAP) was employed using exon
four of CPEB2 as "bait" and incubated with recombinant SRSF3 protein confirmed this
interaction. However, mutation of the consensus sequence abolished the SRSF3
interaction. This assay demonstrated that SRSF3 specifically binds exon four of CPEB2
while competition for SRSF3 binding being achieved with non-biotinylated exon 4 RNA
in excess concentration (100X); with no RNA/protein interaction observed with a
nonspecific competitor RNA (Fig. 1C-D). Furthermore, mutation of the consensus
SRSF3 sequence (CAUCC -> GAGUC) ablated the SRSF3/exon four association (Fig.
1C-D). Importantly, reduced levels of SRSF3 drastically reduced the amount of SRSF3,
which bond the consensus SRSF3 sequence in TNBC cells (Fig. 1E). Together, these
data show that SRSF3 associates specifically with the CPEB2 exon four SRSF3
consensus sequence, CAUCC.

Table 1: RNA trans-splicing factor candidate screen utilizing siRNA for CPEB2A/B
Protein Ratio
Protein
No Treatment
Non-targeting control
SRSF3
hnRNP H1
hnRNP F
hnRNP H1/F

CPEB2A/B ratio
7.40
6.96
19.0
9.78
7.06
3.58
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Figure 1: SRSF3/SRp20 specifically binds to exon four in CPEB2 pre-mRNA.
A) MDA-231 nuclear extract was incubated with either FITC-conjugated CPEB2 exon
four sequence + "cold" nonspecific competitor (FI-CP) or pre-incubated with 100X "cold"
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Figure 1 (continued): CPEB2ex4 as a specific competitor (+SC). Samples were then
electrophoresed, and nuclear proteins bound to CPEB2 exon four RNA were extracted
and subjected to proteomic analysis. B) SRSF3-specific antibody was used for CLIPqRT-PCR to detect CPEB2 levels in either MDA-231 parental or AnR cells. Real-time
PCR to CPEB2 at exon four was evaluated (data represented as n = 3 ± standard
deviation (sd), * = p < 0.05). C) The consensus sequence for SRSF3 and a partial
sequence of exon four highlighting the proposed SRSF3 binding site. D) SBAP assay
was employed to detect SRSF3 bound to CPEB2 exon four. Recombinant SRSF3 was
incubated with biotinylated exon four CPEB2 RNA oligos with either WT or the mutant
SRSF3 ESE cis-element. The samples were incubated with either biotin-labeled
CPEB2 exon four sequence + "cold" nonspecific competitor (NSC) or pre-incubated with
100X "cold" unlabeled CPEB2/exon4 as a specific competitor (+SC). E) An EMSA
analysis of siRNA-depleted expression of SRSF3 in MDA-231 cells. EMSA labels
correspond to MDA-231 cells treated with siRNA control, and then total protein lysates
incubated with wild type CPEB2 exon four ESE RNA (si0-WT), siRNA control-treated
cell lysates incubated with mutant exon four CPEB2 ESE RNA (si0-MUT), siRNA to
SRSF3 treated cell lysates incubated with the wild type CPEB2 exon four ESE RNA
(siSF3-WT), or siRNA to SRSF3 treated cell lysates incubated with mutant CPEB2 exon
four ESE RNA (siSF3-MUT). Control samples were incubated with nonspecific IgG.
The arrows indicate the electrophoretic shift of proteins bound by the anti-SRSF3
antibody or the presence of free FITC-conjugated CPEB2 exon four RNA probe as
labeled.
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Downregulation of SRSF3 Resulted in Reduced Inclusion of Exon Four into the Mature
CPEB2 mRNA Transcript.
To investigate if SRSF3 regulated the exclusion/inclusion of exon four of CPEB2,
siRNA targeting SRSF3, and the other trans-acting splicing factors which were
elucidated via the unbiased proteomic screen, were employed (Fig. 2, Table 1). A total
downregulation of ≥ 75% for each of the proteins was achieved in both the MDA-231
and MDA-468 cell lines (Fig. 2B & 2D, Table 1) with siRNA compared to the nontargeting siRNA controls. The downregulation of the RNA trans-acting factor SRSF3
resulted in a significant increase in the ratio of CPEB2A/B mRNA and proteins, favoring
a decrease of inclusion of exon four in the mature CPEB2 mRNA (Fig. 2A & 2C). The
reduction of SRSF3 protein in the MDA-468 cells, which characteristically express more
endogenous CPEB2B isoform compared to MDA-231 (ratio of CPEB2A/CPEB2B 2.4 vs.
3.3, respectively), also resulted in an increase in the CPEB2A/CPEB2B ration (Fig. 2A &
2C). Together this data demonstrates that the RNA trans-acting factor SRSF3
enhances the inclusion of exon four in the mature CPEB2 mRNA transcript.
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Figure 2: Downregulation of SRSF3 decreases exon four inclusion in endogenous
CPEB2 transcripts and correlates to a loss of CPEB2B protein expression.
A) MDA-468 cells were subjected to nonspecific siRNA treatment (si0) or two different
siRNA specific to SRSF3 (siSF3-1 and siSF3-2), and the endogenous levels of either
CPEB2A (CPA) or CPEB2B (CPB) mature mRNA transcripts were detected by RT-PCR
with primers spanning exon four. B) Western blot analysis of the siRNA treated MDA35

Figure 2 (continued): 468 cells indicates expression of SRSF3 in siRNA depleted
samples. C) MDA-231 cells were treated with siRNA treatment to SRSF3 in duplicate,
then RT-PCR products for endogenous CPEB2 isoform mRNA was quantified via
densitometry. D) Western blot analysis of the siRNA treated samples in MDA-231 cells
indicates expression of SRSF3 in siRNA depleted samples. Percent decrease was
calculated by setting control at 100% then subtracting the signal in the SRSF3 depleted
sample. E) Western blot analysis of the siRNA treated samples in MDA-231 cells
indicates expression of CPEB2 in siRNA depleted samples.

The Consensus RNA cis-element for SRSF3 is Essential for the Inclusion of Exon Four
in CPEB2.
A consensus pentamer nucleotide motif is contained within exon four of CPEB2.
This motif has been implicated as promoting the alternative splicing of pre-mRNAs for
both coding and non-coding transcripts. To investigate the binding of SRSF3 to the
RNA cis-element contained in exon four, a minigene reporter system was designed for
mutational analysis (Fig. 3A). More specifically, exon three, intron three, exon four,
partial intron four, and most of exon five were into the (pcDNA 3.1(-)) mammalian
expression vector containing a CMV promoter. A competitive RT-PCR assay was used
to analyze the exclusion/inclusion of exon four into the minigene mRNA. To ensure
specificity avoiding the amplification of endogenous splicing events, a plasmid-specific
reverse primer was used (Fig. 3A). MDA-231 parental (Par) and anoikis resistant (AnR)
cells were analyzed for their minigene splicing profiles to determine whether the
observed increase in SRSF3 protein levels in AnR cells directly correlated with CPEB2
AS in TNBC. Notably, the minigene expression of CPEB2 in TNBC cells were similar to
36

the CPEB2A/CPEB2B mRNA endogenous ratio (2.3±0.11 for the minigene vs. 2.5±0.09
for endogenous) in MDA-231 Par cells, and the wild-type CPEB2 minigene splicing in
MDA-231 AnR resulted in a similar ratio trend (1.3±0.02 for the minigene vs. 1.7±0.07
for endogenous).
To investigate if SRSF3 expression affected inclusion/exclusion of exon four of
CPEB2, siRNA targeting SRSF3 was used and resulted in a significant increase in the
CPEB2A/CPEB2B minigene mRNA ratio, which mimic the effects which were observed
for the endogenous levels (Fig. 3C-F). The reductions in CPEB2 AS were significant in
the siSRSF3 treatment compared to the siRNA control and equated to an approximate
1.3-1.4-fold decrease in both the Par and AnR cells (p-value = 0.0023 for parental and
p-value = 0.0003 for the anoikis resistant cells).
To demonstrate SRSF3 binding to exon four of CPEB2 is required for the
inclusion of exon four, site-directed mutagenesis was used targeting the punitive SRSF3
cis-element located in exon four (Fig. 4A). Mutations were introduced using nucleotide
substitution with residues which were predicted to abolish binding (see Fig. 1C & D).
Upon mutation of the SRSF3 consensus sequence in exon four, a basal reduction of the
CPEB2A/CPEB2B minigene mRNA ratio was observed for both the MDA-231 Par and
AnR cell lines, with slight variation in amounts (6.0±0.70 and 2.8±0.42, respectively (Fig.
4B & C). Mutation of the cis-acting mRNA factor specific to SRSF3 binding resulted in a
significant reduction of the CPEB2B isoform in the Par and AnR cells (p-value = 0.0007
and 0.0053, respectively). Taken together, these data demonstrate SRSF3 is the transacting factor regulating the inclusion of exon four via association with the mRNA ciselement, CAUCC in TNBC.
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Figure 3: Varying levels of SRSF3 in TNBC cells affects the CPEB2 mRNA isoform ratio
at exon four.
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Figure 3 (continued): A) Schematic of the CPEB2 exon 3-4/5 minigene. Genomic DNA
was amplified from the RPCI-11 Hs BAC Clone using primers that spanned all of exon 3
and 4, and partial of exon 5. The complete intron 3 sequence was included, and partial
amplification of intron 4 was included. Primers that were specific to the minigene were
used to detect splicing events in RT-PCR analysis. B) MDA-231 Par cells were
compared to MDA- 231 AnR cells analyzing basal levels of minigene splicing for the
minigene-specific CPEB2A/CPEB2B minigene ratio and compared to endogenous
CPEB2 splicing (endo). C-D) MDA-231 Par (C) and MDA-231 AnR (D) cells were
treated with siRNA targeting SRSF3. CPEB2 minigene splicing and endogenous
CPEB2 splicing was detected via RT-PCR. E-F. MDA-231 Par (E) and MDA-231 AnR
(F) SRSF3 protein levels were detected after siRNA treatment as indicated by Western
blot. The representative images from the three independent experiments are
presented, and for all quantitation n = 3 ± standard deviation (sd) via densitometry.
Statistical significance is reported as a p-value from oneway ANOVA pooled t-test of the
MG or endo CPEB2A/CPEB2B ratio. (* = p-value < 0.05, ** = p-value < 0.01, *** = pvalue < 0.001).
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Figure 4: A Mutational analysis of SRSF3 RNA cis-element indicates the pentameric
cis-element is essential for the inclusion of exon four in CPEB2.
A) Schematic representation of the mutant minigene. The red bar indicates that the
RNA cis-element is located near the 5' splice site. Genomic coordinates showed the
first nucleotide base in the RNA cis-element and were retrieved from Genome
Reference Consortium Human Build (GRCh38.p12). B) RT-PCR analysis of MDA- 231
Par cells for the wild type (WT) CPEB2 cis-element compared to mutant (Mut)
minigene-specific CPEB2A/CPEB2B ratio. C) An RT-PCR analysis of MDA-231 AnR
cells for the WT CPEB2 cis-element compared to Mut minigene-specific
CPEB2A/CPEB2B ratio. Representative images of three independent experiments are
presented. All quantitation is shown as n = 3 ± standard deviation (sd) via densitometry.
Statistical significance is reported as a p-value from one way ANOVA pooled t-test of
the MG CPA/CPB ratio. (* = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001).
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SRSF3 regulates anoikis sensitivity in TNBC cells by enhancing the inclusion of exon
four in CPEB2 mRNA.
To investigate whether SRSF3 is a key regulatory mediator in acquiring anoikis
resistance (AnR) via CPEB2 AS, downregulation of the SRSF3 protein was analyzed in
both MDA-231 and MDA-469 AnR cell lines. Interestingly, with SRSF3 downregulation,
an increase in basal apoptosis and detached induced cell death was observed in both
AnR cell lines (Fig. 5A-B). Notably, the ectopic expression of CPEB2B (exon four
included) ablated the effect of SRSF3 downregulation (Fig. 5A). Together, these data
establish a link between the mRNA trans-factor SRSF3 binding exon four of CPEB2 and
the acquisition of the AnR phenotype in TNBC. This study provides clear evidence that
the inclusion of exon four, regulated by the SRSF3/CPEB2 AS axis, induces AnR in
TNBC by promoting the CPEB2B mRNA transcript expression.
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Figure 5: SRSF3 modulates TNBC sensitivity to anoikis-mediated cell death due to
expression of CPEB2B.
siRNA treatment was applied for 48-hours then incubated for 6 hours on regular
substrate or poly HEMA substrate, which forced cells into suspension. After incubation,
early-stage apoptosis was analyzed using Western blot to probe for cleaved PARP (clvPARP) and cleaved Caspase 3 (clv-CASP3). Using antibodies for apoptotic markers
detected full-size PARP (116 kDa) and cleaved PARP (89 kDa), and both large
fragments of activated cleaved Caspase 3 (17/19 kDa doublet). A. MDA -231 AnR cells
were treated as indicated in plus/minus graphical organizer with nonspecific siRNA
control (si0), pcDNA3.1(-) empty-vector (pcDNA), siRNA to SRSF3 (siSF3), CPEB2BFlag overexpression plasmid (CPEB2B), and poly-HEMA coated substrate (p-HEMA).
Samples shown representative of experiments done in triplicate for each treatment. B.
MDA-MB-468 AnR cells were treated identically to the cells described in panel A.
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Expression of SRSF3 is enhanced in TNBC and basal-like breast cancer.
The study linking SRSF3 AS regulation of CPEB2 promoting the CPEB2B
isoform in conjunction with our previous reports of CPEB2B high expression levels in
TNBC promote TNBC metastasis, collectively postulate the premise that SRSF3
expression levels will correlate with the aggressiveness of TNBC and other breast
cancer subtypes. To investigate this premise, sequence data obtained from the TCGA
Breast Invasive Carcinoma (BRCA) dataset was examined, looking at unique patient
cases data that contained RNAseq and clinical data for SRSF3 mRNA levels. The
corresponding mRNA z-scores were deduced for each of the PAM50 gene-expressionbased subtypings. The TNBC and also the basal-like subtypes both indicated the
highest SRSF3 mRNA expression levels, while the HER2+, Luminal A, and Luminal B
subtypes expressed significantly less SRSF3 mRNA (Fig. 6A). The R coding platform
was used to interrogate the TCGA data for survival which revealed that stratifying
patients according to SRSF3 mRNA expression was indicative of survival (Fig. 6B).
This data supports the premise that in TNBC with high SRSF3 mRNA expression, the
CPEB2A/CPEB2B isoform ratio will be low. This provides further insight into the vital
role of dysregulated alternative splicing in the progression and metastasis of cancer.
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Figure 6: SRSF3 is over-represented in the most aggressive and metastatic breast
cancers in The Cancer Genome Atlas.
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Figure 6 (continued): A) The mRNA z-scores were derived from patient samples with
both clinical breast cancer subtypes based on PAM50, histopathology, and RNASeq
data in the Breast Invasive Carcinoma (TCGA, Cell 2015) data set containing 1105
patient samples. SRSF3 mRNA expression data across the main breast cancer
subtypes was mined from cBioPortal and evaluated using ANOVA with posthoc Tukey
HSD (** = p-value < 0.01, *** = p-value < 0.0001). B) Clinical overall survival data for
BRCA data set was extracted from TCGA for combined Basal-like and TNBC cohorts,
consisting of 131 patients. Survival probability based on SRSF3 mRNA expression
levels were plotted as a Kaplan-Meyer curve using the cBioPortal. The cases with
alterations are defined as deviating based on mRNA z-scores in the both upper or lower
quantiles of the population. Calculated statistical significance is reported as log-rank
test analysis (p-value = 0.0323).

Discussion
Our laboratory has provided evidence describing a mechanism for CPEB2 AS
regulation by the RNA trans-splicing factor SRSF3 in TNBC. Importantly, SRSF3 is
shown to be upregulated during hypoxia in the TME associated with solid and malignant
breast tumors. Previously, we reported that the two isoforms, CPEB2A and CPEB2B, of
CPEB2, exert opposing roles for TNBC from primary to the metastatic phenotypes via
AnR acquisition. Here we describe, for the first time, that the pro-oncogene SRSF3
promotes the expression of the pro-metastatic CPEB2B mRNA isoform. We have also
identified that the alternative splicing of CPEB2 pre-mRNA is regulated by the binding of
SRSF3 to the pyrimidine-rich, pentameric cis-element found in the distal 3' of exon four.
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This association promotes the inclusion of exon four into the CPEB2B mRNA transcript
leading to activation of signaling pathways important in the initiation of epithelial to
mesenchymal transition (EMT) (Fig. 7). Importantly, SRSF3 splicing regulation of exon
four of CPEB2 is dependent on RNA cis-element sequence fidelity in exon four. Indeed,
we observed a reversal of the CPEB2A/CPEB2B mRNA ratio with a substitution
mutation at the SRSF3 consensus sequence in the CPEB2 minigene. Finally,
modulation of SRSF3 protein levels via siRNA targeting SRSF3 mRNA led to a
decrease in CPEB2B mRNA transcript levels resulting in a reversal of the low
CPEB2A/CPEB2B ratio to the higher ratio observed in the AnR cells. This reversed
ratio resulted in an increase in early apoptosis of the TNBC AnR cells. Introduction of
exogenous CPEB2B expression with the cDNA vector "rescued" AnR by forced growth
in suspension, which is representative of early phenotypic adaptations in cells during
the acquisition of AnR important in the metastasis of TNBC. However, a robust rescue
was not observed in the biological phenotype as predicted by the original hypothesis as
cleaved-PARP levels were not attenuated by circumvention SRSF3 activity via CPEB2
exogenous expression in the siSRSF3 treatment group. This suggests that although
SRSF3 is necessary for CPEB2B isoform generation, the CPEB2B isoform alone is not
sufficient to completely rescue the biological phenotype.
Globally, SRSF3 plays a crucial role in regulating AS events, and increased
levels of SR proteins bound to exon splicing enhancer cis-elements in pre-mRNA
prevent exon skipping [120]. Recent studies elucidate an antagonistic role for SRSF3
that differs from other SR proteins in that SRSF3 promotes exon inclusion during events
such as tumor initiation, progression, resistance to detached induced cell death [121].
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Indeed, these data indicate that SRSF3 is potentially a master transcriptome regulator
due to evidence that SRSF3 can bind with several SR protein family members and
promote a "poison cassette exon" autoregulatory feedback loop via nonsense-mediated
decay (NMB) [122]. While current research shows that CPEB2 AS is connected to
SRSF3 association with an RNA cis-element in exon four of CPEB2 pre-mRNA, this
may not be the only regulatory mechanism for CPEB2 AS. For example, we found short
term transient upregulation of SRSF3 cDNA did not increase CPEB2B mRNA levels in
MDA-231 cells as might be predicted (data not shown). In fact, increased SRSF3
protein levels may be due to chromosomal amplifications in the MDA-231 cell line,
which is pentameric at the SRSF3 6p21.1 locus (MDA-231 SKY/M-FISH SKYGRAM)
[123]. A possible explanation is that extensive post-translational modifications (PTMs)
of oncogenic pathways promote hyperactivation of SRSF3, providing resistance to
proteolytic degradation in TNCB cells. Continued investigation into SRSF3 activity
during various PTMs may elucidate the influence that SRSF3 exerts on lowering the
CPEB2A/CPEB2B isoform ratio seen in TNBC AnR.
Regarding SRSF3 PTMs, neddylation, which is a modification that covalently
links the small ubiquitin-like protein NEDD8 to Lys85 in SRSF3, was shown to promote
stress granule (SG) assembly during oxidative stress [124]. This strategy is co-opted by
tumor cells which are subject to persistent stress to ensure nascent mRNAs and
proteins are compartmentalized and readily available to regulate activation of signaling
pathways. Interestingly, not only is there evidence that SRSF3 localizes to SGs [125],
both CPEB2A and CPEB2B protein contain a low complexity domain (LCD) in their Nterminal intrinsically domains [126]. These LCDs, which are found in other RNA binding
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proteins, may contribute to the formation of sub-organelle compartments like SGs [127].
Additionally, the phosphorylation of SRSF3 in the RS domain is significantly important to
the regulation of spliceosome assembly, and catalysis of AS events are dependent on
dephosphorylation of the SRSF3 RS domain [128]. This
phosphorylation/dephosphorylation cycle also contributes to SRSF3s ability to interact
with nuclear export factor NXF1 to couple the AS and polyadenylation of mRNA during
NXF1-mediated export [129]. In TNBC, where SRSF3 protein levels are high, it may be
hypothesized that CPEB2 activates the acquisition of metastasis by primary tumors if
CPEB2B mRNA is bound at exon four by highly phosphorylated SRSF3 resulting in
CPEB2B shuttling to SGs in the cytoplasm, thereby increasing CPEB2B abundance and
promoting the translation of the HIF1α and TWIST1 transcription factors important in the
activation of EMT.
Defects in AS often impact dysregulation in numerous hallmarks of cancer,
promoting the metastasis of primary tumors. In TNBC, the increased genomic
heterogenicity may result from defects in AS resulting in structural protein variants
which increase therapeutic resistance. Interest in targeting the protein products of
aberrant splicing in cancer and the RNA trans-splicing factors, particularly SRSF3, using
antisense oligonucleotides (ASOs), has grown and may be a promising novel
therapeutic option in cancer treatment [130]. Most certainly, targeting the
SRSF3/CPEB2 paradigm in TNBC is worth pursuing.
In conclusion, we have identified the RNA trans-splicing factor SRSF3 as the AS
regulator responsible for mediating the alternative splicing of CPEB2 via association
with the RNA cis-element in exon four. Our study describes the importance of the
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SRSF3/CPEB2B splicing paradigm in acquiring AnR in TNBC. Additionally, we provide
evidence that depletion of SRSF3 via siRNA results in a loss of AnR and reverts the
CPEB2A/CPEB2B ratio to resemble that of non-tumorigenic breast tissue. Future
studies are necessary to elucidate the activation of this novel splicing event and the
potential therein to translate into a potential target for breast cancer carcinoma.

Figure 7: Proposed pathway for the mechanism of SRSF3 and CPEB2 splicing in the
SRSF3/CPEB2B splicing paradigm constituting progression towards metastatic TNBC.
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CHAPTER 3: THE MECHANISM OF TRANSLATIONAL REGULATION OF HIF1
AND TWIST1 MRNA VIA CPEB2A AND CPEB2B ISOFORMS

Abstract
Triple-negative breast cancer (TNBC) remains the most deadly and aggressive
subtype of breast cancer. Furthermore, TNBC is more common in younger women and
the African American population. Our lab has recently elucidated a role for which the
alternative spliced isoforms of cytoplasmic polyadenylation element-binding protein 2
(CPEB2), CPEB2A, and CPEB2B, regulate the acquisition of anoikis resistance (AnR)
and metastasis in TNBC via translational regulation of hypoxia-inducible factor-alpha
(HIF1) and twist-related transcription factor (TWIST1). Specifically, The CPEB2A
protein isoform inhibits translation of HIF1 and TWIST1 and the CPEB2B isoform
enhances translation of these transcription factors contributing to the metastatic
cascade. In this study, the mechanism of HIF1 and TWIST1 translational regulation
via CPEB2A and CPEB2B was examined. We determined that the CPEB2A isoform
bound to the CPE sites located in HIF1 and TWIST1 3'UTR mRNA and interacted with
known polyadenylation complex proteins. Similarly, we found CPEB2B associated with
polyadenylation complex proteins, albeit a weaker interaction, but did not bind CPE
sites in HIF1 and TWIST1 3'UTR mRNA. We also found that CPEB2A and CPEB2B
localize to both the nucleus and cytoplasm. Furthermore, we identified novel protein
interactions for CPEB2B, specifically exon four, which is absent in the CPEB2A
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transcript. CPEB2B was shown to interact with proteins, specifically, the translation
invitation factor eIF3H and heteronuclear-ribonuclear proteins hnRNPR and hnRNPF/H,
which have been identified as IRES trans-acting factors (ITAFs) important in capindependent translational activation of mRNAs in cellular stress events. Interestingly,
we also identified a strong interaction between CPEB2A and CPEB2B proteins
suggesting a potential connection between the CPEB2 alternative splicing regulation
and translational activation/inhibition of HIF1 and TWIST1. These novel interactions
have never been described and provide evidence that alternative splicing inducing a
ratio shift of CPEB2A to CPEB2B proteins results in translational activation of HIF1
and TWIST1 mRNA through an IRES-mediated cap-independent translational
mechanism promoting the acquisition AnR and the metastatic phenotype in TNBC.

Introduction
TNBC is a breast cancer subtype that is characterized histologically by its lack of
the estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor
receptor 2 (HER2) [131]. Compared to other breast cancer subclasses containing these
hormone receptors, TNBC exhibits significant genetic complexity and tumor
heterogenicity, which renders treatment with targeted chemotherapeutics ineffective
[132]. Common treatment options for TNBC, such as neoadjuvant chemotherapy, may
initially prove relatively successful; however, TNBC commonly acquires resistance to
chemotherapeutics contributing to the lowest five-year progression-free and survival
rates of all breast cancer subtypes [133]. TNBCs aggressive nature, combined with its
poor prognosis, makes the discovery of novel treatments imperative.
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Investigation of CPEB2 has uncovered an anti-neoplastic and suppressive role in
regulating translation of HIF1 and TWIST1 mRNA [134]. However, it has become
apparent that these findings are for the CPEB2A isoform. Indeed, our lab has published
that dysregulated CPEB2 AS, marked by an increase in the CPEB2B isoform which
promotes translation of HIF1 and TWIST1 mRNA, is prevalent in TNBC tumor
samples [135]. Corresponding in vivo analysis indicated that a splicing ratio shift
favoring expression of the CPEB2B isoform, which includes exon four in the mRNA
transcript, contributed anoikis resistance (AnR), detachment-induced cell death,
promoting tumor metastasis to the lung. Furthermore, we have shown that these splice
variants regulate hypoxia and EMT in an opposing fashion through translational
regulation of HIF1 and TWIST1 mRNA, transcription factors important in regulating
these pathways [136]. However, the mechanism by which translational regulation is
accomplished remains elusive.
Cytoplasmic polyadenylation element-binding protein 2 (CPEB2) is a member of
the CPEB family of proteins that mediate polyadenylation of mRNA targets in the
cytoplasm [137]. There are four family members in the CPEB protein family (1-4)
divided into two categories based on protein sequence similarity. CPEB1 belongs to the
first category and is the most distinct of the CPEB family members, whereas the second
category consisting of CPEB2, CPEB3, and CPEB4 are closely related [138]. In terms
of structure, all CPEB proteins are comprised of three regions: they have an N-terminal
domain characterized as intrinsically disordered, highly structured c-terminal domains
which contain two RNA recognition motifs (RRMs) and a cysteine-histidine region
resembling a zinc finger [139]. The RRMs of CPEB proteins bind consensus
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cytoplasmic polyadenylation element (CPE) sequences in 3' untranslated regions (UTR)
mRNA, the most common of which is UUUUUAU [140]. A nuclear role for CPEB
proteins, specifically CPEB1 and CPEB4, has been suggested in which these proteins
bind to their targeted mRNAs in the nucleus, and the CPEB/mRNA complex is then
exported to the cytoplasm [141]. In this manner, the CPEB protein can exhibit tight
translational regulation of mRNAs crucial to stress responses.
As mentioned previously, the N-terminal end of the CPEB proteins are
characterized as intrinsically disordered, and tier sequences vary significantly amongst
the family members [142]. In CPEB1, the N-terminal region was shown to associate
with proteins that belong to the polyadenylation complex, specifically GLD2 and PARN,
and with the cap-binding eukaryotic initiation factor four E (eIF4E) [143]. This
mechanism describes how CPEB1 regulates the translation of target mRNA. Richter
and colleges demonstrated that CPEB1 binds the 3'UTR CPE sites in mRNA and
interacts with the polyadenylation complex proteins GLD2 and PARN [144]. PARN, a
deadenylating enzyme, outcompetes the poly(A) polymerase activity of GLD2, inhibiting
the polyadenylation of the mRNA [145].
Additionally, CPEB1 interacts with a cap-binding protein, eIF4E, inhibiting the
eIF4E/eIF4G interaction, synonymous with cap-dependent mRNA translation initiation,
inhibiting the recruitment of the 43s preinitiation complex and thereby halting translation
initiation [146]. Phosphorylation of CPEB1 via Aurora kinase results in a conformational
change and disassociation with PARN, which then allows for GLD2 to polyadenylate
mRNA [147]. Furthermore, CPEB1 phosphorylation also results in eIF4E release
allowing interaction with eIF4G and recruitment of the 43s preinitiation complex and
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initiating translation [148]. However, the mechanism for mRNA translation regulation by
the other CPEB family members (2-4) differs from CPEB1, partly due to the absence of
an Aurora kinase phosphorylation site in the N-terminal domain [149].
Progress towards understanding its mechanism of translational regulation of mRNA by
CPEB2 has been reported. Chen and colleagues reported that CPEB2 (presumably the
CPEB2A isoform) inhibits translation of hypoxia-inducible factor one-alpha (HIF1) via
association with its 3'CPE region and by binding to eukaryotic elongation factor 2
(eEF2) in Neuro 2A (N2A) murine cells. Upon oxidative stress, an interaction between
CPEB2 (eEF2) is halted, allowing the ribosome to continue translation [150]. Another
study by Nairisgami and colleagues proposed a mechanism of translational regulation
by CPEB2 for Twist Family BHLH Transcription Factor 1 (TWIST1) in MCF-10A nonmalignant breast epithelial cells [151]. In this mechanism, CPEB2 and CPEB1 regulate
TWIST1 mRNA translation via association with CPE sites, of which there are two in the
3'UTR of TWIST1 mRNA, allowing polyadenylation of TWIST1 mRNA. Association with
both CPE sites allows for the inclusion of microRNA (miRNA) regulatory binding sites,
resulting in reduced TWIST1 protein translation.
Our lab has published findings indicating that the CPEB2 isoforms have opposing
effects on the translation of HIF1 and TWIST1 mRNA. Furthermore, we have shown
that ectopic expression of CPEB2B did not result in robust increases in HIF1 and
TWIST1 mRNA nor proteolytic turnover. These results suggest a link between mRNA
binding and the regulation of translational activity of the CPEB2A/B transcripts. Taken
together, we hypothesized that the inclusion of exon four in CPEB2, the CPEB2B
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isoform, changes the mRNA binding and that exon four is associating with novel protein
complexes important in promoting the translation of mRNA.
In this study, our laboratory demonstrated that CPEB2A but not CPEB2B
associates with 3'UTR CPE sites located in HIF1 and TWIST1 mRNA. Surprisingly,
the binding of the CPEB2A isoform but not the CPEB2 isoform results in
polyadenylation of TWIST1 mRNA; however, no differences in HIF1 mRNA
polyadenylation was observed. We also found that CPEB2A and CPEB2B localize to
both the nucleus and the cytoplasm, which indicate a nuclear role for CPEB2 similar to
that which has been previously described for CPEB1 and CPEB4 [152].
We have also identified novel interactions with proteins identified as internal
ribosome entry site (IRES) trans-acting factors (ITAFs), which are important in
regulating IRES cap-independent translation of mRNAs in stress response pathways
[153], with exon four of the CPEB2B isoform. Furthermore, we have identified that
CPEB2A and CPEB2 proteins interact with each other. Taken together, these novel
findings suggest that CPEB2B may bind CPEB2A inhibiting CPEB2As activity as a
translational repressor and promoting CPEB2Bs function as a translational activator
through an IRES-mediated cap-independent mechanism of transitional regulation.
These findings provide evidence that shifts in the AS of CPEB2 towards increased
CPEB2B isoform production promotes HIF1 and TWIST1 mRNA translation via
CPEB2A/CPEB2B competitive interaction and activation of IRES cap-independent
translation.
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Material and Methods
Cell culture and reagents:
MDA-231 and MDA-468 cells were obtained from ATCC (Manassas, VA) and
maintained in RPMI (Invitrogen). The cell lines were supplemented with 10% fetal
bovine serum (FBS, Invitrogen) and 1% Penicillin / Streptomycin (Invitrogen). Cell lines
were maintained in a 95% air / 5% CO2 incubator at 37°C. Cells were passaged once
every 3-5 days (~90% confluence), and all experiments were performed during the first
12 passages.

Western Blotting:
Total protein (10-30 μg) was electrophoretically separated on 10% SDSpolyacrylamide gels. Samples were transferred electrophoretically to PVDF
membranes, then probed with the appropriate antibody (anti-3xFlag, eIF3H, eIF4/G,
hnRNPR, hnRNPF/H, HA antibodies purchased from Cell Signaling.

Plasmid construction:
The 3xFlag-CPEB2A and 3xFlag-CPEB2A and the HA-CPEB2B plasmid
constructs were previously reported. Briefly, genomic DNA fragments were amplified
using standard PCR conditions and proofreading Taq polymerase (Phusion High
Fidelity DNA Polymerase, New England Biolabs). The PCR conditions consisted of a
denaturing step of 98 C for 30 seconds followed by 30 cycles, 98 C denaturing for 10
sec., 60 C annealing for 30 seconds, 72 C extension for 30 sec., and final extension
step at 72 C for 10 min. Site-directed mutagenesis was performed using the
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QuickChange II XL Site-Directed Mutagenesis Kit (Agilent) according to the
manufacturer's instructions along with primers containing either the 3xflag-tag sequence
(5'GACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGATTACAAGGATG
ACGATGACAAG3') or the HA-tag sequence (5'TACCCATACGATGTTCCAGATTAC
GCT 3'). Fusion of amplified genomic DNA material with the pcDNA3.1(+) mammalian
vector (Invitrogen) was accomplished using the In-Fusion HD cloning reaction
(Clontech). With each step of PCR amplification and plasmid generation. All the
primers used in cloning were synthesized by Integrated DNA Technologies (IDT).

Plasmid Transfection:
All transfections were performed in duplicate with 10-cm tissue culture dishes.
The plasmid transfections were accomplished using the Lipofectamine 3000 lipid-based
transfection system (ThermoFisher) according to the manufacturer's instructions and
using 5.0 g total DNA per 10-cm tissue culture dish.

UV Cross-linking and Co-immunoprecipitation:
UV crossing-linking and co-immunoprecipitation of bound mRNA to CPEB2A and
CPEB2B were performed according to previously described protocol []. Briefly, MDA231 cells transfected with either 3xflag-CPEB2A or 3xflag-CPEB2B constructs were
irradiated with 200 mJ UV and harvested. Lysates were incubated with anti-3xflag
magnetic agarose beads (Millipore), followed by three stringent washes with a high-salt
buffer wash and two washes with 1XPBS (Fisher). Bound mRNA was eluted with
phenol-chloroform and purified with an mRNA purification kit (Zymogen).
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Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR):
Primer/probe sets targeting the 5'UTR of HIF1 and TWIST1 mRNA were
purchased from Integrated DNA Technologies. PCR was performed as described [154].
cDNA synthesis was accomplished using the Superscript III kit (Life Technologies)
according to the manufacturer's instructions. Samples were amplified with the Bio-Rad
CFX Connect qPCR machine and then calculated using the standard curve method.

RNA Binding Assays:
3'UTR Wild-type (WT) biotinylated RNA TWIST1 CPE sequences 1 and 2
(Bi:5'GUGAGAUCUAGUUUGCAGUUGCCAGCUUGGGGCUCAGAUUCACUCCAAGA
UAGUUGGUGCACUGCAGCCGGAACAUCCAGAAUAGACCAG3') and HIF1 CPE
sequence(bi:5'GUGAGAUCUAGUUUGCAGUUGCCAGCUUGGGGCUCAGAUUCACU
CCAAGAUAGUUGGUGCACUGCAGCCGGAACAUCCAGAAUAGACCAG) were
incubated with 3xFlagCPEB2A or 3xFlagCPEB2B transfected MDA-231 cell lysates,
and RNA-bound proteins were precipitated as described [155]. Samples were subjected
to immunoblotting with 10% polyacrylamide gels with an anti-flag antibody
(ThermoFisher).

USB Poly(A) Tail-Length Assay:
USB Poly(A) Tail-Length Assay Kit (ThermoFisher) and manufactures
instructions were used to determine poly(A) tail-length of HIF1 and TWIST1 mRNA.
Briefly, MDA-231 cells were transfected with 3xFlagCPEB2A or 3xFlagCPEB2B, and
mRNA was extracted. G/I tailing of mRNA was completed by adding Tail Stop Solution
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and incubating at 37 for 60 minutes. Poly(G/I) tailed RNA was then subjected to
RTPCR to produce cDNA transcripts. PCR of Poly(G/I) tailed cDNA was completed
using primer sets designed to amplify poly(A) tail regions as described (Fig. 9-10).

Co-immunoprecipitation and Proteomic Analysis:
Co-immunoprecipitation was accomplished as previously described. Briefly,
MDA-231 and MDA-468 cells lysates with transiently expressed 3xFlag-CPEB2A or
3xFlag-CPEB2B were incubated with anti-3xflag magnetic agarose beads (Millipore)
followed by three stringent washes with a high-salt buffer wash and two washes with
1XPBS (Fisher). Bound proteins were eluted with (200ng/mL) 3xflag peptide
(ThermoFisher) and subjected to proteomic analysis at the University of South Florida
proteomics core (Tampa, FL). Statistical analysis of results was analyzed via Ingenuity
Pathway Analysis (IPA).

CPEB2 Exon four Binding Assay:
Wild-type (WT) biotinylated exon four CPEB2B peptide sequence
(5'VRSSLQLPAWGSDSLQDSWCTAAGTSRIDQ3') were incubated with MDA-231, and
MDA-468 cellular lysates and bound proteins were precipitated as described [156].
Samples were subjected to immunoblotting with 10% polyacrylamide gels with
antibodies targeting specific proteins.
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Immunofluorescence:
Immunofluorescence was carried out with MDA-231 cells stably expressing either
Flag-CPEBA or Flag-CPEB2B plasmids on coverslips for 24 hours and then fixed with
4% paraformaldehyde. The primary antibodies used for immunofluorescence were
Alexa fluor 488 rabbit monoclonal anti-flag antibody (1:1000). The nuclei were
visualized by DAPI (Sigma, St. Louis, MO). Images were taken using a Keyence BZ-X
series microscope (Itasca, IL).

Subcellular Fractionation Assay:
Subcellular fractionation was performed using the subcellular protein
fractionation kit (Thermo Scientific) according to the manufacturer's instructions. Briefly,
MDA-231 cell lysates transiently expressed 3xFlag-CPEB2A or 3xFlag-CPEB2B and
treated with either arsenic (2ng/mL) or H2O (control) for 16 hours were separated
according to the manufacturer's kit instructions. Western blot analysis of fractionated
samples was accomplished with 10% polyacrylamide gels and immunoblotted with
either anti-3xflag, anti-tubulin, anti-Lamin, or anti-Clv-Parp antibodies (Cell Signaling).

Results
CPEB2A binds to CPE 1 and 2 sites of TWIST1 and CPE 1 site of HIF1 3' UTR and
regulates polyadenylation.
Previously, our lab reported that CPEB2A and CPEB2B isoforms of CPEB2
regulate the translation of HIF1 and TWIST1 mRNA in an opposing manner. These
findings led to the investigation of the mechanism driving CPEB2Aand CPEB2B

60

translational regulation of HIF1 and TWIST1 mRNA. To this end, a streptavidin-biotin
affinity pull-down assay (SBAP) was utilized to determine binding affinities of the
CPEB2A and CPEB2B protein isoforms for the 3'UTR CPE sites in HIF1 (CPE1) and
TWIST1 (CPE1 and CPE2) (Fig. 8B & 9B).
Transfection of Flag-CPEB2A resulted in significant binding to HIF1 (CPE1) and
both TWIST1 (CPE1 and CPE2) sites (Fig. 8B & 9B). Conversely, transfection of FlagCPEB2B did not show an affinity for HIF1 (CPE1) and neither TWIST1 (CPE1 and
CPE2) sites (Fig. 8B & 9B). This assay revealed that the CPEB2A protein isoform binds
to the CPE regions of HIF1 and TWIST1 3'UTR, with competition for CPEB2A binding
achieved with unlabeled HIF1 (CPE1) and TWIST1 (CPE1 and CPE2) RNA at access
concentration (100x); while nonspecific competitor RNA showed no effect on the RNA:
protein complex (Fig. 8B & 9B).
Additionally, while the CPEB2B protein isoform showed no binding affinity for
HIF1 and TWIST1 CPE1 sites, it did indicate minimal binding to the CPE2 site of
TWIST1 3' UTR. Competition for CPEB2B binding was achieved with unlabeled HIF1
(CPE1) and TWSIT1 (CPE1 and CPE2) RNA at access concentration (100x), while
nonspecific competitor RNA showed no effect on the RNA: protein complex (Fig. 8B &
9B). These data demonstrate that the CPEB2A protein isoform binds to the HIF1 and
TWIST1 3' CPE1 and TWIST1 CPE2 3'UTR mRNA while revealing a difference in
binding affinity differences for the CPEB2 isoforms.
To investigate if potential differences in CPEB2A and CPEB2B regulation of
HIF1 and TWIST1 polyadenylation of mRNA, a poly(A) tail length assay was used.
RNA of MDA-231 cells transfected with either Flag-CPEB2A or Flag-CPEB2B were
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analyzed via RT-PCR with primers designed to target the HIF1 polyadenylation site
(pA1) and the three polyadenylation sites of TWIST1 (pA1, pA2, and pA3) (Fig. 8A &
9A). Over-expression of CPEB2A resulted in no change in polyadenylation of HIF1
pA1 compared to the control and increased polyadenylation of TWIST1 mRNA at the
pA2 and pA3 sites (Fig. 8C & 9C). Over-expression of the CPEB2B protein isoform
resulted in no change in polyadenylation to either the HIF1 pA1 or TWIST1 (pA1, pA2,
and pA3) sites compared to the control (Fig. 8C & 9C). These results demonstrate the
differential regulation of polyadenylation of HIF1 and TWIST1 3'UTRs by the CPEB2A
and CPEB2B protein isoforms.

Figure 8: CPEB2A and CPEB2B HIF1 3'CPE binding differs but poly(A) of HIF1
mRNA by both CPEB2 isoforms is consistent.
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Figure 8 (continued): A) A graphical representation of HIF13'UTR mRNA indicating the
CPE site (CPE1) and polyadenylation site (pA1) located in the 3' HIF1 UTR. Primer
design scheme for poly(A) tail length assay is also represented. B) SBAP assay was
used to detect Flag-CPEB2A (CPA) and Flag-CPEB2B (CPB) bound to CPE sequence
1 of HIF1 3' UTR. MDA-231 cells were transfected with Flag-CPEB2A or FlagCPEB2B plasmids and harvested after 48 hrs. Lysates were incubated with biotinylated
HIF1 CPE 1 sequence RNA oligo. Samples were incubated with biotin-labeled HIF1
CPE 1 sequence + "cold" nonspecific competitor (NSC) or pre-incubated with 100X
"cold" unlabeled HIF1 CPE1 3'UTR RNA as a specific competitor (+SC). C) USB
Poly(A) Tail-Length Assay was used to determine poly(A) tail length of HIF1 mRNA.
MDA-231 cells were transfected with Flag-CPEB2A (CPA) or Flag-CPEB2B (CPB), and
RNA was extracted. G/I tailing of RNA was completed by adding Tail Stop Solution and
incubating at 37C for 60 minutes. Poly(G/I) tailed RNA was then subjected to RT-PCR
to produce cDNA transcripts. PCR of Poly(G/I) tailed cDNA was completed using
primer sets designed to amplify poly(A) tail regions as described in (A).
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Figure 9: CPEB2A and CPEB2B TWIST1 3'CPE mRNA binding and poly(A) differ.
A) A graphical representation of TWIST1 3'UTR mRNA indicating the CPE sites (CPE1,
CPE2) and polyadenylation sites (pA1, pA2, pA3) located in the 3' TWIST1 UTR.
Primer design scheme for poly(A) tail length assay is also represented. B) SBAP assay
was used to detect Flag-CPEB2A (CPA) and Flag-CPEB2B (CPB) bound to CPE
sequences 1 and 2 (CPE1, CPE2) of TWIST1 3' UTR. MDA-231 cells were transfected
with Flag-CPEB2A or Flag-CPEB2B plasmids and harvested after 48 hrs. Lysates were
incubated with either biotinylated TWIST1 CPE1 or CPE2 sequences RNA oligos.
Samples were incubated with biotin-labeled TWIST1 CPE1 or CPE2 sequences + "cold"
nonspecific competitor (NSC) or pre-incubated with 100X "cold" unlabeled TWIST1
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Figure 9 (continued): CPE1 or CPE2 3'UTR RNA as a specific competitor (+SC). C)
USB Poly(A) Tail-Length Assay was used to determine poly(A) tail length of TWIST1
mRNA. MDA-231 cells were transfected with Flag-CPEB2A (CPA) or Flag-CPEB2B
(CPB), and RNA was extracted. G/I tailing of RNA was completed by adding Tail Stop
Solution and incubating at 37C for 60 minutes. Poly(G/I) tailed RNA was then subjected
to RT-PCR to produce cDNA transcripts. PCR of Poly(G/I) tailed cDNA was completed
using primer sets designed to amplify poly(A) tail regions as described in (A).

CPEB2A and CPEB2B associate with polyadenylation complex proteins.
To investigate potential interaction with polyadenylation complex proteins which
have been previously described as associating with CPEB proteins and regulating
translation of mRNAs, a co-immunoprecipitation assay was used. MDA-231 cell lysates
with transiently expressing Flag-CPEB2A or Flag-CPEB2B were subjected to pull-down
with anti-3xflag magnetic agarose beads and immunoblotting (Fig. 10A). The results
indicated that CPEB2A and CPEB2B associate with the polyadenylation complex
proteins GLD2 and PARN with no difference in affinities between the CPEB2A and
CPEB2B isoforms detected (Fig. 10A). Furthermore, neither the CPEB2A nor the
CPEB2B protein isoforms associated with the eukaryotic initiation factors eIF4E and
eIF4G (Fig. 10A), which are essential in the cap-dependent mechanism of mRNA
translation. This was surprising as it has previously been reported that CPEB1
indirectly binds eIF4E, inhibiting eIF4Es recruitment of the preinitiation complex.
To determine differences in CPEB2A and CPEB2B novel protein interactions, coimmunoprecipitation followed by proteomic analysis was employed. MDA-231 cell
lysates with transiently expressing Flag-CPEB2A or Flag-CPEB2B were subjected to
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pull-down with anti-3xflag magnetic agarose beads, and bound proteins were analyzed
by proteomic analysis. This resulted in the identification of the hnRNP proteins
hnRNPR and hnRNPF/H, and the eukaryotic initiation factor 3H (eIF3H) as having a
stronger association with the CPEB2B isoform (Fig. 10 B&C). Additionally, the
association of hnRNPR with CPEB2 was significantly more robust (*p-value 0.003) than
with CPEB2A (Fig. 10D). Interestingly, hnRNPR was previously reported as an ITAF
associated with IRES-mediated cap-independent translation of HIF1 mRNA. Also,
eIF3Hs association with the preinitiation complex suggests that CPEB2Bs interaction
with these proteins may promote activation of the cap-independent translation
mechanism.

A

B

D
C

Figure 10: CPEB2B forms novel protein complexes.
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Figure 10 (continued): A) Co-immunoprecipitation assays were performed using conical
members of the polyadenylation complex. MDA-231 cell lysates transiently expressing
Flag-CPEB2A or Flag-CPEB2B were exposed to anti-Flag-bound magnetic beads. The
pull-down fraction was immunoblotted (IB) and compared to the (pcDNA3.1) (+) empty
vector (EV) control. B-C) Co-immunoprecipitation immunoblotting of the novel proteins
identified by proteomic analysis compared to the control (EV). D) The representative
image for statistical significance analysis of hnRNPR bound to CPEB2B. Quantitation n
= 4 ± standard deviation (sd) via densitometry. Statistical significance is reported as a
p-value from oneway ANOVA pooled t-test (* = p-value < 0.05, ** = p-value < 0.01, *** =
p-value < 0.001).

CPEB2A and CPEB2B localize to the nucleus and cytoplasm.
A previously described nuclear role for CPEB proteins, specifically CPEB1 and
CPEB4, suggested that these proteins bind to their targeted mRNAs in the nucleus, and
the CPEB/mRNA complex is then exported to the cytoplasm. In this manner, the CPEB
protein can exhibit tight translational regulation of mRNAs crucial to stress responses.
To investigate the localization of the CPEB2A and CPEB2B protein isoforms, an
immunofluorescent assay was used. MDA-231 cells transiently expressing either FlagCPEB2A or Flag-CPEB2B were analyzed via microscopic analysis for nuclear and/or
cytoplasmic localization (Fig. 11A). We found that both the CPEB2A and CPEB2B
localized to the nucleus and cytoplasm (Fig. 11A). Examination of CPEB2A and
CPEB2B under stress conditions was accomplished via a sub-cellular fractionation
assay (Fig. 12). MDA-231 cells transiently expressing Flag-CPEB2A or Flag-CPEB2B
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were subjected to either 2ng/mL arsenic or H2O (control) for 16 hrs. Cell lysates were
subjected to sub-cellular fraction and immunoblotted. The results indicated that
CPEB2A and CPEB2B localized to both the cytoplasm (Fig. 12A) and the nucleus (Fig.
12B), and their localization is independent of cellular stress events (Fig. 12 A & B).
These results suggest a nuclear and cytoplasmic role for CPEB2A and CPEB2B
irrespective of cellar stress.

Figure 11: Nuclear and Cytoplasmic Localization of CPEB2A and CPEB2B.
MDA-231 cells stably expressing either Flag-CPEBA or Flag-CPEB2B were
cultured on coverslips for 24 hours and then fixed with 4% paraformaldehyde. Cells
were incubated with Alexa fluor 488 rabbit monoclonal antibody. Nuclei were with by
DAPI. Images were taken using a Keyence BZ-X series microscope.
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Figure 12: CPEB2A and CPEB2B protein isoforms localize to the cytoplasm and
nucleus independent of cellular stress.
Subcellular fractionation was performed on MDA-231 cell lysates transiently expressed
Flag-CPEB2A or Flag-CPEB2B and treated with either arsenic (2ng/mL) or H2O
(control) for 16 hours. A) MDA-231 cytoplasmic fraction was subjected to immunoblot
analysis with indicated antibodies. B) MDA-231 cytoplasmic fraction was subjected to
immunoblot analysis with indicated antibodies. Quantitation n = 2 ± standard deviation
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Figure 12 (continued): (sd) via densitometry. Statistical significance is reported as a pvalue from oneway ANOVA pooled t-test (* = p-value < 0.05, ** = p-value < 0.01, *** =
p-value < 0.001).

CPEB2A and CPEB2B protein association.
Although direct interaction amongst CPEB proteins nor indirect interaction via
association with the same complex has never been reported, we investigated this
potential using co-immunoprecipitation. Mda-231 cells transiently expressing FlagCPEB2A and HA-CPEB2B were subjected to pull-down with anti-3xflag magnetic
agarose beads and immunoblotted (Fig. 13). Surprisingly, the results indicate that HACPEB2B either directly interacts or maybe interacting with a protein complex in which
Flag-CPEB2A is bound (Fig. 13).

Figure 13: CPEB2A and CPEB2 protein interaction
A) Input: MDA-231 cell lysates transiently expressing Flag-CPEB2A (CPA) and HACPEB2B (CPB) were incubated with anti-Flag-bound magnetic beads and
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Figure 13 (continued): immunoblotted for indicated proteins. B) Pull-down fraction was
immunoblotted (IB) and compared to the (pcDNA3.1) (+) empty vector (EV) control.

Discussion
As presented herein, our laboratory has provided insight into the differential
regulatory function of CPEB2A and CPEB2B in the context of HIF1α and TWIST1A
mRNA binding and expression, including describing a mechanism for their translational
regulation by the CPEB2 protein isoforms in TNBC. We have previously described a
mechanism whereby altered mRNA splicing of CPEB2, via association with the transsplicing factor serine-arginine splicing factor 3 (SRSF3), differentially regulates
translation of HIF1α and TWIST1 mRNA, transcription factors crucial to the metastatic
progression of TNBC. Specifically, we have previously reported that CPEB2A
decreases TWIST1 and HIF1α protein levels. Conversely, we have reported that
CPEB2B dramatically increases TWIST1 and HIF1α protein levels corresponding to an
increase in the metastatic phenotype.
In this thesis, we describe the differential RNA binding displayed by the two
CPEB2 isoforms. Specifically, the CPEB2A protein isoform binds 3'CPE sequences in
both HIF1α and TWIST1; however, surprisingly, we observed limited to no binding
affinity of CPEB2B to the CPE regions of HIF1α and TWIST1 as predicted by our
original hypothesis. Furthermore, we show differences in 3' UTR poly(A) regulation of
TWIST1 mRNA between the CPEB2A and CPEB2B isoforms. Specifically,
overexpression of the CPEB2A isoform results in poly(A) extension of the TWIST1
3'UTR compared to the control. However, we did not see this result in the CPEB2B
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overexpressing samples, which more closely resembled the TWIST1 poly(A) length in
the control. These results were surprising as it is well characterized that CPEB
proteins, upon binding to CPE sites of target mRNA species, inhibit their
polyadenylation and subsequently their translation. Typically, under stress conditions,
phosphorylation of CPEB proteins allows for mRNA polyadenylation and increased
translation.
Interestingly, we observe that CPEB2A regulates the polyadenylation of TWIST1
in non-stress conditions by allowing the polyadenylation of TWIST1, which is not
consistent with the original hypothesis. Taken together, these data suggest that
CPEB2A regulates the translation of TWIST1 via binding to the TWIST1 3'UTR,
promoting TWIST1 polyadenylation and decreasing translation. Indeed, Nairismägi and
colleagues reported that translational suppression of TWIST1 was accomplished by
CPEB1, CPEB2 (presumably CPEB2A isoform, as this study was carried out in MCF10A cells), and mi-580 [157]. TWIST1 contains two CPE sequences within the 3'UTR
and binding of both of these sequences by the CPEB (1,2) proteins promote the
inclusion of regulatory miRNA sites within the 3'UTR of TWIST1 mRNA. In this manner,
the association of CPEB1/CPEB2/miRNA results in reduced expression of TWIST1
protein. We have shown that CPEB2A associates strongly with both CPE elements in
the TWIST1 3'UTR and that increased CPEB2A reduces translation of TWIST1 mRNA.
We proposed that this result may be due to the miRNA site found between the two CPE
sites in TWIST1 3'UTR (Fig.14).
As we seek to explain why overexpression of the CPEB2B protein isoform results
in increased TWIST1 mRNA translation, we note that it has been well documented that
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shortened poly(A) tails of mRNAs essential to stress response pathways promotes their
rapid translation [158]. Indeed, it is plausible that whereas CPEB2A inhibits TWIST1
mRNA translation ploy(A) extension and subsequent inclusion of miRNA sites, CPEB2
may indirectly reduce poly(A) tail length of TWIST1 mRNA and increase its translation
(Fig. 14). This finding is evidence for a novel function of the CPEB2 isoforms in
regulating translation through differing polyadenylation of TWIST1 mRNA.
We have also demonstrated that CPEB2 (exon four included) associates with
proteins that have been reported as IRES trans-acting factors (ITAFs) important in
IRES-mediated cap-independent translation [159]. Indeed, our proteomic analysis of
proteins bound to CPEB2B found that the CPEB2B protein isoform associates with the
translation initiation factor eIF3H and the hnRNP proteins hnRNPR and hnRNPF/H.
Interestingly, hnRNPR has been shown to function as an ITAF in promoting IRES capindependent translation of mRNA [160]. Furthermore, we found that CPEB2B is
associated with the translation initiation factors eIF4E or eIF4G, critical regulatory
proteins in the cap-dependent translation mechanism [161]; however, we did find
CPEB2B associated with eIF3H, which interacts with the preinitiation complex.
Furthermore, an IRES site has been reported in the 5'UTR of HIF1α mRNA, activating
the cap-independent translation of HIF1α mRNA [162]. Taken together, these findings
suggest a mechanism by which CPEB2B interacts with known ITAFs, activating the
IRES cap-independent mechanism of translation HIF1α.
Here we also report that the CPEB2A and CPEB2B protein isoforms interact with
each other. This novel finding was very surprising as interactions amongst CPEB
proteins have not been described. This interaction provides evidence of a
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CPEB2A/CPEB2B axis of translational regulation of mRNA. In this mechanism, an
alternative splicing switch promoting an increase in the CPEB2B isoform allows for
increased binding to CPEB2A, thus blocking translational inhibition of HIF1α and
TWIST1 mRNA while CPEB2B interacts with the ITAF (hnRNPR) and recruits the 43S
preinitiation complex via association with eIF3H and promotes rapid translation in an
IRES cap-independent mechanistic fashion (Fig. 15).
We have shown that CPEB2A and CPEB2B interact and that CPEB2B is
associated with the hnRNPR, hnRNPF/H, and eIF3H proteins. Since hnRNP proteins
are multifunctional in both the nucleus and cytoplasm and a nuclear role for CPEB
proteins has been described, we wanted to determine if CPEB2A and/or CPEB2B also
can localize to the nucleus. Interestingly, we found that both CPEB isoforms are indeed
localized to the nucleus and cytoplasm. This finding was intriguing and suggests
CPEB2A may bind nuclear HIF1α and TWIST1 mRNA before being shuttled out to the
cytoplasm. In this manner, CPEB2 can exhibit tight translational control of the mRNAs.
Furthermore, we previously found that siRNA targeting hnRNPF/H bound to and
promoted the inclusion of exon four in the CPEB2 pre-mRNA transcript (CPEB2B)
(Table 1). Here we also reported that the CPEB2B protein isoform was found to
associate with hnRNPF/H. This suggests an additional level of CPEB2 regulation in
which CPEB2B may bind nuclear hnRNPF/H and inhibit its association with exon four
and allowing association with SRSF3 with exon four of CPEB2 pre-mRNA, thus
promoting inclusion of exon four in the CPEB2 transcript (CPEB2B).
In conclusion, we have identified a novel mechanism for HIF1 and TWIST1
mRNA translational regulation by the CPEB2A and CPEB2B isoforms. The mechanism
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described here demonstrates that the CPEB2A/CPEB2B interaction directly relates to
translational activation or inhibition of HIF1 and TWIST1. A splicing switch favoring the
production of CPEB2B leads to increased HIF1 and TWIST1 translation, promoting the
acquisition of AnR and metastasis in TNBC. Additionally, we provide evidence that the
regulation of translation begins in the nucleus by the binding of CPEB2A to the mRNA
of HIF1 and TWIST1. We have also provided evidence that CPEB2B make act in a
regulatory feedback loop through binding hnRNPF/H in the nucleus and promoting
increased CPEB2B production. Future studies are necessary to investigate potential
binding motifs within the CPEB2 proteins, allowing their dimerization. This study
provides insight into the regulatory process governing the translational control of HIF1a
and TWIST1 mRNA and TNBC progression and its potential therein to translate to novel
therapeutic targets for the treatment of breast cancer carcinoma.

TWIST1 mRNA

miRNA site

Figure 14: CPEB2A protein isoform inhibits TWIST1 mRNA translation.
CPEB2A inhibits the translation of TWIST1 mRNA by binding both CPE elements
located in TWIST1 3'UTR, promoting poly(A) and inclusion of miRNA regulatory sites
between the CPE sites.
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Figure 15: Mechanism of Translational regulation by CPEB2A/CPEB2B interaction and
IRES cap-independent translational activation.
CPEB2A and CPEB2B protein isoforms locate the nucleus. CPEB2A binds target
mRNA and is exported to the cytoplasm, where it interacts with the poly(A) protein
complex (GLD2 and PARN) and inhibits translation. Increases levels of the CPEB2B
isoform binds the A isoform and interacts with hnRNPF/H, which is then exported. In the
cytoplasm, CPEB2B interaction the ITAF hnRNPR, recruits the 43s preinitiation
complex through eIF3H interaction, and initiates cap-independent translation.
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CHAPTER 4: DISCUSSION AND CONCLUSIONS

TNBC is a heterogeneous cancer with high morbidity and mortality. This
heterogeneity increases the complexity of its clinicopathological features and influences
the survival and outcomes of this disease. Further attempts to classify TNBC into the
basal-like subtype (1-2) (BL1 and BL2), mesenchymal-like and mesenchymal stem-like
(M and MSL), and luminal androgen receptor (LAR) subclasses have been made.
These classification attempts aim to generate “precision” treatment approaches based
on specific genetic and biochemical targets to increase favorable outcomes for TNBC
patients. As an example, the BL1/BL2 subtypes display increased expression of genes
that promote cell proliferation and DNA damage repair, which allows for focused clinical
trials using antimitotic and DNA-damaging agents. Furthermore, the IM subtype of
TNBC has been treated using monoclonal antibodies, activating an immune response
towards cells that display high immunogenicity and neoantigen expression. It's
estimated that over ninety percent of TNBC tumors overexpress the TROP2
glycoprotein, which promotes proliferation, invasion, and survival. The use of an
antibody-drug conjugate with active irinotecan metabolite to treat TNBC resulted in a
thirty percent overall response rate and an overall survival rate of 16.6 months in
patients displaying metastatic TNBC. These examples provide evidence that targeted
(or “personalized”) treatment of TNBC based on the patient's molecular profile is a
viable option in pursuing increased survival and outcomes of the disease. The studies
presented in this dissertation attempt to improve our understanding of crucial regulatory
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pathways active in TNBC progression, specifically during the early earliest phases of
metastasis when cells depend on the acquisition of anoikis resistance and EMT to
invade surrounding tissue and enter circulation. Two genes critical to these processes,
HIF1α and TWIST1, are translationally activated to promote these phenotypes. These
genes both contain CPE consensus sequences within their 3'UTR mRNA, in which
binding of the CPEB1 protein represses their translation in maturing oocytes. It was
also demonstrated that the CPEB2 member of the CPEB family binds to the HIF1α and
TWIST1 3'PE sites. In chapter two of this dissertation, we demonstrated that the splice
variants of CPEB2, CPEB2A, and CPEB2B interact with the 3'CPE sites in HIF1α and
TWIST1; however, CPEB2Bs interaction is significantly weaker. These interactions
directly influence the transitional fate of HIF1α and TWIST1 mRNAs.
A characteristic of TNBC and other cancer types is their ability to hijack
alternative splicing pathways and promote transcriptome changes beneficial to their
growth and survival. As a crucial regulator of pre-mRNA splicing, the global transsplicing factor SRSF3 is estimated to have over two hundred splicing targets. We have
demonstrated that SRSF3 mRNA levels are significantly increased in TNBC compared
to other breast cancer subtypes in the BRCA cohort of TCGA. Examination of this
cohort also revealed that alteration of SRSF3 expression correlates to reduced survival.
Furthermore, SRSF3 protein expression is enhanced after acquisition of anoikis
resistance in multiple TNBC cell lines. While these data provide evidence that SRSF3
affects the metastatic phenotype of TNBC in vitro, in humans, the effects may be more
subtle due in part to the effects of post-translational modification of SRSF3 and its
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function. Therefore, it would be useful to examine protein kinases regulating SRSF3
phosphorylation at the RS domain in future studies.
Interestingly, patients that exhibited the lowest SRSF3 expression levels were
either stage II or stage III, stages in which lymph node involvement is common, and
micrometastases are generally present. While these patients may exhibit low SRSF3
expression in the primary tumor, a different expression profile may be found in
metastatic sites. Future investigations combining PTM status, profiling of metastatic
RNA, and pathological staging taken in concert may better predict patient outcomes.
In chapter two, we endeavored to elucidate a mechanism to determine the
location of SRSF3 binding within exon four of the CPEB2 pre-mRNA, thereby promoting
its inclusion in the CPEB2B mature mRNA transcript. In TNBC anoikis-resistant cells,
increased SRSF3 protein levels directly correlate with a decrease in the
CPEB2A/CPEB2B isoform ratio implicating SRSF3 as the RNA trans-factor modulating
the AS of CPEB2. In addition, reduced SRSF3 expression via siRNA increased the
CPEB2A/CPEB2B ratio (reduced exon four inclusion) in both MDA-231 parental and
anoikis resistant cells. We also identified an RNA cis-element in exon four in which
SRSF3 binds and mutation of this cis-element ablated interaction with SRSF3. We
further investigated this result by designing a minigene reporter construct which allowed
for modulation of SRSF3 in a manner that mimics endogenous CPEB2A and CPEB2B
isoform expression, and that mutation of the CPEB2 RNA cis-element increased the
CPEB2A/CPEB2B isoform ratio in vitro. We were able to "rescue" the anoikis-resistant
phenotype in TNBC cells that were treated with siSRSF3 by overexpression of the
CPEB2B isoform. Taken together, we see evidence that SRSF3 acts as the trans-
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splicing factor regulating the AS of CPEB2 via binding an RNA cis-element in exon four
of CPEB2 in TNBC.
In chapter three, we investigated the mechanism of translational regulation by the
CPEB2A and CPEB2B isoforms. First, we explored the potential of the CPEB2
isoforms to bind to conserved CPE sequences in the 3'UTR of HIF1α and TWIST1
mRNA since both CPEB2 isoforms contain identical conserved RBD's in their C-terminal
ends. We reported that the CPEB2A protein isoform binds 3'CPE sequences in both
HIF1α and TWIST1, but the CPEB2B isoform displayed a weak interaction. We also
reported an increase in poly(A) of TWIST1 3'UTR corresponding to CPEB2A binding
both CPE sequences. We propose that this result is due to a miRNA site found
between the two CPE sites in TWIST1 3'UTR results in a decrease in TWIST1 mRNA
translation and an increase in anoikis sensitivity in TNBC. With regards to the CPE
sequence binding potential of the CPEB2B isoform, further investigation is needed. We
have previously reported that increased CPEB2B protein levels promote the translation
of both HIF1α and TWIST1 mRNA; however, we saw that the CPEB2B isoform
interaction with the CPE sequence in TWIST1 and HIF1α was weak how then is
CPEB2B regulating their translation.
A potential answer was found when we investigated possible protein interaction
differences between the two isoforms. Using co-immunoprecipitation and proteomic
analysis, we identified numerous proteins which showed a strong binding affinity for
CPEB2B but not CPEB2A. We identified these proteins as important trans-factors in
IRES cap-independent translation. Also, we found via co-immunoprecipitation that the
CPEB2A and CPEB2B isoforms were interacting with each other. This finding was
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certainly unique and revealed the potential of a novel mechanism for translational
regulation of mRNA by CPEB2. We propose that CPEB2A binds 3' CPE sequences in
targeted mRNA and inhibits their translation; however, upon interaction with the
CPEB2B isoform and its binding of ITAF factors, IRES cap-independent translation is
initiated. This would also explain CPEB2Bs weak interaction with 3'CPE sequences of
mRNA as it is bound to CPEB2A, which has a strong affinity to the CPE sequences of
HIF1α and TWIST1.
Furthermore, we reported that CPEB2A and CPEB2B localize to both the
nucleus and the cytoplasm. This finding was not novel for the CPEB2A protein isoform
as a nuclear function for the CPEB family member CPEB1 has been reported in which
CPEB1 binds nuclear mRNA before export, thereby eliciting tight translational control of
targeted mRNA. However, it is surprising in the CPEB2B protein isoform context since
we demonstrated a weak interaction of CPEB2B and 3' CPE sequences within HIF1α
and TWIST1 mRNA. The answer to this question may lie in the details of our chapter
two findings. When we analyzed potential trans-splicing factors bound to exon four of
CPEB2 pre-mRNA using a siRNA screen, we found that knock-down of hnRNPF/H
resulted in a reduced ratio in CPEB2A/CPEB2B mRNA transcripts. Later in chapter
three, we detailed a strong affinity between the CPEB2B and hnRNPF/H proteins. We
now think it is plausible that CPEB2B may bind nuclear hnRNPF/H in the nucleus
initiating a regulator feedback loop. In this mechanism, the CPEB2B isoform binds to
nuclear hnRNPF/H, thereby reducing the levels of available hnRNPF/H to bind the exon
four sequence of CPEB2 pre-mRNA. This mechanism, combined with increases in
SRSF3, promotes rapid and robust CPEB2B mRNA isoform expression. The increased
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presence of the CPEB2B allows for increased CPEB2A/CPEB2B interaction, resulting in
increased translational activation of HIF1α and TWIST1 mRNA.
Although these conclusions still need a considerable amount of investigation for
confirmation, the mechanism would provide significant insight into the role of CPEB
proteins and their mechanism of translational regulation.
With the seemingly limitless potential of bioinformatics, advances in the treatment
of TNBC based on precision medicine have been limited and still rely, in large part, on
systemic delivery of chemotherapeutics. Biomedical research's continued and future
goal is to focus on tailoring patient therapy by utilizing the genetic profiles of individual
cancer subsets. As bioinformatic technologies including transcriptomics, immuneomics, radiomics as well as other “omics” become less expensive, their use will allow for
individual tumor analysis and will help provide treatment guidance for patients. For
example, this approach could be used to investigate the dysregulated cellular pathways
which define the tumor's genetic signature and help guide treatment options towards
therapeutics which target those pathways. Indeed, a recent clinical trial using this
approach found that inhibition of the PD-L1 immune checkpoint via treatment with
atezolizumab (monoclonal anti-PD-L1 antibody) yielded positive results in TNBC
treatment. The research contained herein provides new insight into the dysregulated
cellular pathways which promote the aggressive nature of TNBC and contribute to
potential treatment strategies in the clinic. These insights allow for the possibility of
developing novel therapeutics targeting unique aspects of both the transcriptome and
proteome with consideration of specific sequence properties and molecular interactions
of TNBC metastatic progression.
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